[go: up one dir, main page]

WO2006003147A1 - Phthalazine derivatives as parp inhibitors - Google Patents

Phthalazine derivatives as parp inhibitors Download PDF

Info

Publication number
WO2006003147A1
WO2006003147A1 PCT/EP2005/053030 EP2005053030W WO2006003147A1 WO 2006003147 A1 WO2006003147 A1 WO 2006003147A1 EP 2005053030 W EP2005053030 W EP 2005053030W WO 2006003147 A1 WO2006003147 A1 WO 2006003147A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
hydrogen
compounds
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/053030
Other languages
French (fr)
Inventor
Laurence Anne Mevellec
Ludo Edmond Josephine Kennis
Josephus Carolus Mertens
Jacobus Alphonsus Josephus Van Dun
Maria Victorina Francisca Somers
Walter Boudewijn Leopold Wouters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200700192A priority Critical patent/EA014955B1/en
Priority to MXPA06014542A priority patent/MXPA06014542A/en
Priority to CA2569824A priority patent/CA2569824C/en
Priority to CN2005800222580A priority patent/CN1980674B/en
Priority to EP05761151.9A priority patent/EP1771175B1/en
Priority to UAA200612975A priority patent/UA93351C2/en
Priority to BRPI0512902-8A priority patent/BRPI0512902A/en
Priority to HK07110953.7A priority patent/HK1105586B/en
Priority to NZ551799A priority patent/NZ551799A/en
Priority to ES05761151.9T priority patent/ES2563954T3/en
Priority to US11/569,889 priority patent/US7803795B2/en
Priority to AU2005259189A priority patent/AU2005259189B2/en
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to JP2007518607A priority patent/JP4852540B2/en
Publication of WO2006003147A1 publication Critical patent/WO2006003147A1/en
Priority to IL180410A priority patent/IL180410A/en
Anticipated expiration legal-status Critical
Priority to NO20070557A priority patent/NO20070557L/en
Priority to US12/856,218 priority patent/US8946221B2/en
Priority to US14/540,363 priority patent/US20150072972A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to inhibitors of PARP and provides compounds and compositions containing the disclosed compounds. Moreover, the present invention provides methods of using the disclosed PARP inhibitors for instance as a medicine.
  • PARP-I nuclear enzyme poly(ADP-ribose) polymerase-1
  • PARP-I 1 PARP-2, PARP-3 and Vault-PARP Tankyrases
  • TANKs Tankyrases
  • PARP is also referred to as poly(adenosine 5'-diphospho-ribose) polymerase or PARS (poly(ADP-ribose) synthetase).
  • PARP-I is a major nuclear protein of 116 kDa consisting of three domains : the N- terminal DNA binding domain containing two zinc fingers, the automodification domain and the C-terminal catalytic domain. It is present in almost all eukaryotes.
  • the enzyme synthesizes poly(ADP-ribose), a branched polymer that can consist of over 200 ADP-ribose units.
  • the protein acceptors of poly(ADP-ribose) are directly or indirectly involved in maintaining DNA integrity. They include histones, topoisomerases, DNA and RNA polymerases, DNA ligases, and Ca 2+ - and Mg 2+ -dependent endonucleases.
  • PARP protein is expressed at a high level in many tissues, most notably in the immune system, heart, brain and germ-line cells. Under normal physiological conditions, there is minimal PARP activity. However, DNA damage causes an immediate activation of PARP by up to 500-fold.
  • Tankyrases were identified as components of the human telomeric complex. They have also been proposed to have a role in vesicle trafficking and may serve as scaffolds for proteins involved in various other cellular processes. Telomeres, which are essential for chromosome maintenance and stability, are maintained by telomerase, a specialized reverse transcriptase. TANKs are (ADP-ribose)transferases with some features of both signalling and cytoskeletal proteins.
  • TRF-I Telomere Repeat binding Factor-1
  • TANK functions as a positive regulator of telomere length., allowing elongation of the telomeres by telomerase.
  • PARP and PARG form a cycle that converts a large amount of NAD + to ADP-ribose.
  • over-stimulation of PARP can cause a drop of NAD + and ATP to less than 20% of the normal level.
  • Such a scenario is especially detrimental during ischaemia when deprivation of oxygen has already drastically compromised cellular energy output.
  • Subsequent free radical production during reperfusion is assumed to be a major cause of tissue damage.
  • Part of the ATP drop which is typical in many organs during ischaemia and reperfusion, could be linked to NAD + depletion due to poly( ADP-ribose) turnover.
  • PARP or PARG inhibition is expected to preserve the cellular energy level thereby potentiating the survival of ischaemic tissues after insult.
  • PARP inhibitors suppress production of inducible nitric oxide synthase (iNOS) in macrophages, P-type selectin and intercellular adhesion molecule-1 (ICAM- 1) in endothelial cells. Such activity underlies the strong anti-inflammation effects exhibited by PARP inhibitors.
  • PARP inhibition is able to reduce necrosis by preventing translocation and infiltration of neutrophils to the injured tissues.
  • PARP is activated by damaged DNA fragments and, once activated, catalyzes the attachment of up to 100 ADP-ribose units to a variety of nuclear proteins, including histones and PARP itself.
  • NAD + is depleted by massive PARP activation, in the efforts to re-synthesize NAD + , ATP may also become depleted.
  • PARP activation can also be used as a measure of damage following neurotoxic insults resulting from exposure to any of the following inducers like glutamate (via NMDA receptor stimulation), reactive oxygen intermediates, amyloid ⁇ -protein, N-methyl-4- ⁇ henyl-l,2,3,6-tetrahydropyridine (MPTP) or its active metabolite N-methyl-4 phenylpyridine (MPP + ), which participate in pathological conditions such as stroke, Alzheimer's disease and Parkinson's disease.
  • inducers like glutamate (via NMDA receptor stimulation), reactive oxygen intermediates, amyloid ⁇ -protein, N-methyl-4- ⁇ henyl-l,2,3,6-tetrahydropyridine (MPTP) or its active metabolite N-methyl-4 phenylpyridine (MPP + ), which participate in pathological conditions such as stroke, Alzheimer's disease and Parkinson's disease.
  • MPTP N-methyl-4- ⁇ henyl-l,2,3,6-tetrahydro
  • glutamate which serves as the predominate central nervous system neurotransmitter and acts upon the N-methyl D-aspartate (NMDA) receptors and other subtype receptors, most often occurs as a result of stroke or other neurodegenerative processes.
  • Oxygen deprived neurons release glutamate in great quantities during ischaemic brain insult such as during a stroke or heart attack.
  • N- methyl-D-aspartate NMDA
  • AMPA N- methyl-D-aspartate
  • Kainate MGR receptors
  • open ion channels open ion channels and permit uncontrolled ion flow (e.g., Ca 2+ and Na + into the cells and K + out of the cells) leading to overstimulation of the neurons.
  • the over-stimulated neurons secrete more glutamate, creating a feedback loop or domino effect which ultimately results in cell damage or death via the production of proteases, lipases and free radicals.
  • Glutamate exposure and stimulation has also been implicated as a basis for compulsive disorders, particularly drug dependence.
  • Evidence includes findings in many animal species, as well as in cerebral cortical cultures treated with glutamate or NMDA, that glutamate receptor antagonists (i.e., compounds which block glutamate from binding to or activating its receptor) block neural damage following vascular stroke.
  • NMDA, AMPA, Kainate and MGR receptors have proven difficult because each receptor has multiple sites to which glutamate may bind and hence finding an effective mix of antagonists or universal antagonist to prevent binding of glutamate to all of the receptor and allow testing of this theory, has been difficult.
  • many of the compositions that are effective in blocking the receptors are also toxic to animals.
  • the stimulation of NMDA receptors by glutamate for example, activates the enzyme neuronal nitric oxide synthase (nNOS), leading to the formation of nitric oxide (NO), which also mediates neurotoxicity.
  • NMDA neurotoxicity may be prevented by treatment with nitric oxide synthase (NOS) inhibitors or through targeted genetic disruption of nNOS in vitro.
  • NOS neuronal nitric oxide synthase
  • neuropathic pain such as that induced by chronic constriction injury (CCI) of the common sciatic nerve and in which transsynaptic alteration of spinal cord dorsal horn characterized by hyperchromatosis of cytoplasm and nucleoplasm (so-called "dark” neurons) occurs.
  • CCI chronic constriction injury
  • PARP inhibitors are useful for treating inflammatory bowel disorders, such as colitis. Specifically, colitis was induced in rats by intraluminal administration of the hapten trinitrobenzene sulfonic acid in 50% ethanol. Treated rats received 3- aminobenzamide, a specific inhibitor of PARP activity. Inhibition of PARP activity reduced the inflammatory response and restored the morphology and the energetic status of the distal colon.
  • PARP inhibitors are useful for treating arthritis. Further, PARP inhibitors appear to be useful for treating diabetes. PARP inhibitors have been shown to be useful for treating endotoxic shock or septic shock.
  • PARP inhibitors have also been used to extend the lifespan and proliferative capacity of cells including treatment of diseases such as skin aging, Alzheimer's disease, atherosclerosis, osteoarthritis, osteoporosis, muscular dystrophy, degenerative diseases of skeletal muscle involving replicative senescence, age-related muscular degeneration, immune senescence, AIDS, and other immune senescence disease; and to alter gene expression of senescent cells.
  • diseases such as skin aging, Alzheimer's disease, atherosclerosis, osteoarthritis, osteoporosis, muscular dystrophy, degenerative diseases of skeletal muscle involving replicative senescence, age-related muscular degeneration, immune senescence, AIDS, and other immune senescence disease.
  • PARP inhibitors such as 3-amino benzamide, affect overall DNA repair in response, for example, to hydrogen peroxide or ionizing radiation.
  • PARP inhibitors have been reported to be effective in radiosensitizing (hypoxic) tumor cells and effective in preventing tumor cells from recovering from potentially lethal and sublethal damage of DNA after radiation therapy, presumably by their ability to prevent DNA strand break rejoining and by affecting several DNA damage signaling pathways.
  • the present invention provides compounds, compositions for, and methods of, inhibiting PARP activity for treating cancer and/or preventing cellular, tissue and/or organ damage resulting from cell damage or death due to, for example, necrosis or apoptosis.
  • the compounds and compositions of the present invention are especially useful in enhancing the effectiveness of chemotherapy and radiotherapy where a primary effect of the treatment is that of causing DNA damage in the targeted cells.
  • EP 156433 published on October 2, 1985 discloses pyridazinamines.
  • the described compounds have anti-viral properties. More in particular compounds No. 77, No.
  • This invention concerns compounds of formula (I)
  • the dotted line represents an optional bond
  • n 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
  • each X is independently -N ⁇ or -CH ⁇ ; and when X is -CH ⁇ then Y is -N ⁇ , or -NH-;
  • each Y is independently -N ⁇ , -NH-, -CH ⁇ or -CH2-; except when X is -CH ⁇ then Y is -N ⁇ , or -NH-;
  • L 1 is a direct bond or a bivalent radical selected from -Ci -6 alkanediyl-NH-, -NH- or -NH-Ci -6 alkanediyl-NH-;
  • L 2 is a direct bond or a bivalent radical selected from -Ci ⁇ alkanediyl-, -C 2 - 6 alkenediyl-, carbonyl or -Q-ealkanediyl- substituted with one substituent selected from hydroxy or aryl;
  • 'K 1 is hydrogen, nitro, halo or amino
  • R 2 is hydrogen, C h alky] or arylCi- ⁇ alkyl
  • the central be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
  • Z is hydrogen, hydroxy, Ci ⁇ alkyl, C ⁇ alkyloxy, aryloxy, amino, cyano, arylCi-galkylamino or benzthiazolylCCi.galkytyamino or a ring system selected from
  • R 4 and R 5 are each independently selected from hydrogen, halo, C 1-6 alkyl, Ci -6 alkyloxy or trihalomethyl;
  • aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, Ci ⁇ alkyl or Q- ⁇ alkyloxy;
  • halo is generic to fluoro, chloro, bromo and iodo; trihalomethyl defines methyl containing three identical or different halo substituents for example trifluoromethyl; C ⁇ alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, e.g.
  • -C ⁇ alkanediyl- defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof such as, 2- methylpentanediyl, 3-methylpentanediyl, 2,2-dimethylbutanediyl, 2,3- dimethylbutanediyl and the like; -C 2 _ 6 alkenediyl- defines bivalent straight and branched chain hydrocarbon radicals containing one double bond and
  • pharmaceutically acceptable salts means pharmaceutically acceptable acid or base addition salts.
  • the pharmaceutically acceptable acid or base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and non-toxic base addition salt forms which the compounds of formula (T) are able to form.
  • the compounds of formula (I) which have basic propejrties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g.
  • hydrochloric or hydrobromic acid sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, ⁇ -aminosalicylic, pamoic and the like acids.
  • the compounds of formula (I) which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a suitable organic or inorganic base.
  • Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • the terms acid or base addition salt also comprise the hydrates and the solvent addition fo ⁇ ns which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • stereochemically isomeric forms of compounds of formula (I), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess.
  • chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound.
  • All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
  • N-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide, particularly those N-oxides wherein one or more of the piperidine- or piperazine nitrogens are N-oxidized.
  • a first group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply: a) n is 0, 1 or 2; b) R 2 is hydrogen or arylQ- ⁇ alkyl; c) Z is hydrogen, C ⁇ alkyl, Q-ealkyloxy, aryloxy, amino, cyano, arylCi- ⁇ alkylamino or benzthiazolyl(Ci.6alkyl)amino or a ring system selected from (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10).
  • a second group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply: a) Q is -CR 3 - wherein R 3 is halo or C h alky!; b) each X is -CH ⁇ ; c) each Y is independently -N ⁇ or -NH-; d) L 1 is a bivalent radical selected from -Ci- ⁇ alkanediyl-NH-, -NH- or
  • L 2 is a bivalent radical selected from -Ca-ealkenediyl-, carbonyl or -Ci-galkanediyl- substituted with aryl; f) R 1 is nitro, halo or amino; g) R 2 is arylCi-6alkyl; h) Z is Ci- ⁇ alkyloxy, aryloxy, amino, cyano, arylQ- ⁇ alkylamino or benzthiazolyl(Ci- 6 alkyl)amino or a ring system selected from (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10).
  • L 2 is a bivalent radical selected from -Ci ⁇ alkanediyl-, -C 2 -6alkenediyl-, carbonyl or -Ci- ⁇ alkanediyl- substituted with one substituent selected from hydroxy or aryl; g) R 1 is nitro, halo or amino; h) R 2 is Ci -6 alkyl or arylCi -6 alkyl; i) Z is hydrogen, hydroxy, Ci ⁇ alkyl, Ci-galkyloxy, aryloxy, amino, cyano, arylCi. 6 alkylamino or benzthiazoIyl(Ci. 6 alky])arnino or a ring system selected from
  • R i l is hydrogen;
  • R 2 is hydrogen, arylCi -6 alkyl;
  • Z is hydrogen, Ci_salkyloxy, aryloxy, amino, or a ring system selected from (a-2) or (a-3);
  • R 4 and R 5 are each independently selected from hydrogen or halo.
  • the most preferred compounds are compounds No. 41, No. 13, No. 62, No. 26, No.
  • the compounds of formula (I) can be prepared according to the general methods described in EP156433.
  • the starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art.
  • the reaction can be performed in a suitable solvent such as, for example, an alcohol, e.g. methanol, ethanol, propanol and the like.
  • a suitable solvent such as, for example, an alcohol, e.g. methanol, ethanol, propanol and the like.
  • the compounds of formula (I), wherein Y is -N ⁇ and L is the bivalent radical -Ci -6 alkanediyl- substituted with hydroxy, herein referred to as compounds of formula (I-b), can be prepared by reacting an intermediate of formula (V), wherein t is an integer with value 0, 1, 2, 3 or 4, with a compound of formula (I), wherein L 2 is a direct bond and Z is hydrogen, herein referred to as compounds of formula (I-c).
  • the reaction can be performed in a reaction-inert solvent such as, for example, N,N-dimethylformamide and the like or an alcohol, e.g. propanol and the like.
  • an appropriate base such as, for example, an alkali or earth alkaline metal carbonate or hydrogen carbonate, e.g. triethylamine or sodium carbonate, may be utilized.
  • the compounds of formula (I), wherein Y is -N ⁇ and L 2 is the optionally substituted bivalent radical -Cj- ⁇ alkanediyl-, herein referred to as compounds of formula (I-d), can be prepared by reductively N-alkylating the compounds of formula (I-c), wherein r is an integer with value 0, 1, 2, 3, 4 or 5 with an appropriate carbonyl intermediate of formula (VIII).
  • Said reductive N-alkylation reaction may conveniently be carried out by catalytically hydrogenating a stirred and heated mixture of the reactants in a suitable reaction-inert organic solvent according to art-known catalytic hydrogenating procedures.
  • Suitable solvents are, for example, alcohols, e.g.
  • methanol, ethanol, 2-propanol and the like cyclic ethers, e.g. 1,4-dioxane and the like; halogenated hydrocarbons, e.g. thrichloromethane and the like; N 5 N- dimethylformamide; dimethyl sulfoxide and the like; or a mixture of 2 or more of such solvents.
  • an appropriate catalyst such as, for example, palladium-on-charcoal, platinum-on-charcoal and the like.
  • catalyst-poison to the reaction mixture, e.g., thiophene and the like.
  • Catalytic hydrogenating procedures can also be utilized for the preparation of compounds of formula (I) wherein Z-L 2 - is aminoCi- ⁇ alkyl, herein referred to as compounds of formula (I-i), by converting compounds of formula (I) wherein Z-L 2 - is cyano-(CH 2 )r wherein s is an integer with value 1, 2, 3, 4 or 5, herein referred to as compounds of formula (I-j).
  • the reaction is carried out under hydrogen atmosphere and in the presence of Raney Nickel in a mixture of methanol and ammonia.
  • the compounds of formula (I-c) can also be prepared by deacylating the compounds of formula (I) wherein Z-L 2 - is -Ci-galkyloxycarbonyl, herein referred to as compounds of formula (I-f), by reacting the starting material with an appropriate acidic or basic solution, such as hydrocloric acid or hydrogen bromide, in a suitable solvent e.g. an alcohol, such as propanol.
  • an appropriate acidic or basic solution such as hydrocloric acid or hydrogen bromide
  • the compounds of formula (I), wherein Y is -N ⁇ , herein referred to as compounds of formula (I-k), can be prepared by reacting a compound of formula (I-c), with an intermediate of formula (XI), wherein W is an appropriate leaving group such as, for example, halo, e.g. fluoro, chloro, bromo or iodo, or a sulfonyloxy radical such as methylsulfonyloxy, 4-mefhylphenylsulfonyloxy and the like.
  • the reaction can be performed in a reaction-inert solvent such as, for example, an alcohol, e.g.
  • an ether e.g. 4, 4-dioxane, l,l'-oxybispropane and the like
  • a ketone e.g. 4-methyl-2-pentanone
  • N,N- dimethylformamide or nitrobenzene and the like.
  • an appropriate base such as, fo ⁇ example, an alkali or earth alkaline metal carbonate or hydrogen carbonate, e.g. triethylamine or sodium carbonate, may be utilized to pick up the acid which is liberated during the course of the reaction.
  • a small amount of an appropriate metal iodide e.g., sodium or potassium iodide may be added to promote the reaction. Stirring may enhance the rate of the reaction.
  • the reaction may conveniently be carried out at a temperature ranging between room temperature and the reflux temperature of the reaction mixture and, if desired, the reaction may be carried out at an increased pressure.
  • the compounds of formula (I), wherein X is >N- or L 1 is -Ci-6alkanediyl-NH-, -NH- (e.g) or -NH-Ci- ⁇ alkanediyl-NH-, herein referred to as compounds of formula (1-1), can be prepared by reacting an intermediate of formula (IX), with an intermediate of formula (X) wherein W is as described above.
  • the compounds of formula (I) may also be converted into each other via art-known reactions or functional group transformations. Some of such transformations are already described hereinabove. Other examples are hydrolysis of carboxylic esters to the corresponding carboxylic acid or alcohol; hydrolysis of amides to the corresponding carboxylic acids or amines; hydrolysis of nitriles to the corresponding amides; amino groups on imidazole or phenyl may be replaced by a hydrogen by art-known diazotation reactions and subsequent replacement of the diazo-group by hydrogen; alcohols may be converted into esters and ethers; primary amines may be converted into secondary or tertiary amines; double bonds may be hydrogenated to the corresponding single bond; an iodo radical on a phenyl group may be converted in to an ester group by carbon monoxide insertion in the presence of a suitable palladium catalyst.
  • Intermediates of formula (II) can be prepared by reacting an intermediate of formula (III) with a suitable l(3i ⁇ )-isobenzofuranone of formula (IV) in a mixture of sodium and a suitable solvent such as for example, an alcohol, e.g. ethanol and the like.
  • the present invention also relates to compounds for use as a medicine wherein said compounds are compounds of formula (I)
  • the dotted line represents an optional bond
  • n 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
  • each X is independently - ⁇ or -CH ⁇ ; and when X is -CHk then Y is -N ⁇ , or -NH-;
  • each Y is independently -N ⁇ , -NH-, -CH ⁇ or -CH 2 -; except when X is -CH ⁇ then Y is -N ⁇ , or -NH-;
  • L 2 is a direct bond or a bivalent radical selected from -Ci ⁇ alkanediyl-, -C 2 -6alkenediyl-, carbonyl or -Ci- ⁇ alkanediyl- substituted with one substituent selected from hydroxy or aryl;
  • R 1 is hydrogen, nitro, halo or amino
  • R 2 is hydrogen, Ci ⁇ alkyl or arylCi- ⁇ alkyl
  • the central ' moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
  • Z is hydrogen, hydroxy, C]. 6 alkyloxy, aryloxy, amino, cyano, arylCi_ 6 alkylamino or benzthiazolyl(Ci.6alkyl)amino or a ring system selected from
  • R 4 and R 5 are each independently selected from hydrogen, halo, Cu ⁇ alkyl, C ⁇ ealkyloxy or trihalomethyl;
  • aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, Q-ealkyl or Q ⁇ alkyloxy;
  • the compounds of the present invention have PARP inhibiting properties as can be seen from the experimental part hereinunder.
  • PARP is used herein to mean a protein having poly-ADP-ribosylation activity. Within the meaning of this term, PARP encompass all proteins encoded by a parp gene, mutants thereof, and alternative slice proteins thereof. Additionally, as used herein, the term “PARP” includes PARP analogues, homologues and analogues of other animals.
  • PARP includes but is not limited to PARP-I.
  • PARP-2 includes but is not limited to PARP-I.
  • PARP-3 Vault-PARP (PARP-4), PARP-7 (TiPARP), PARP-8, PARP-9 (BaI), PARP-10, PARP-Il, PARP-12, PARP-13, PARP-14, PARP-15, PARP-16,
  • TANK-I, TANK-2, and TANK-3 may be encompassed.
  • Compounds that inhibit both PARP-I and tankyrase 2 can have advantageous properties in that they have enhanced growth inhibiting activities in cancer cells.
  • the present invention also contemplates the use of compounds in the preparation of a medicament for the treatment of any of the diseases and disorders in an animal described herein, wherein said compounds are compounds of formula (I)
  • the dotted line represents an optional bond
  • n 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
  • each X is independently - ⁇ or -CH ⁇ ; and when X is -CH ⁇ then Y is -N ⁇ , or -NH-;
  • each Y is independently -N ⁇ , -NH-, -CH ⁇ or -CH 2 -; except when X is -CH ⁇ then Y is -N ⁇ , or -NH-;
  • L 1 is a direct bond or a bivalent radical selected from -Ci_ 6 alkanediyl-NH-, -NH- or -NH-Ci -6 alkanediyl-NH-;
  • L 2 is a direct bond or a bivalent radical selected from -C L galkanediyl-, -Ca- ⁇ alkenediyl-, carbonyl or -Ci-ealkanediyl- substituted with one substituent selected from hydroxy or aryl;
  • R 1 is hydrogen, nitro, halo or amino
  • R 2 is hydrogen, Ci-galkyl or arylCi- ⁇ alkyl
  • the central ⁇ " moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
  • Z is hydrogen, hydroxy, C ⁇ alkyl, Ci ⁇ alkyloxy, aryloxy, amino, cyano, arylCi. 6 alkylamino or benzthiazolyl(Ci- 6 alkyl)amino or a ring system selected from
  • R >4 . and, D R5 are each independently selected from hydrogen, halo, Ci- ⁇ alkyl, Ci ⁇ alkyloxy or trihalomethyl;
  • aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, Ci ⁇ alkyl or Ci ⁇ alkyloxy.
  • the compounds of the present invention may be used as reference compounds or tracer compounds in which case one of the atoms of the molecule may be replaced with, for instance, a radioactive isotope.
  • compositions of this invention an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included.
  • Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
  • Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • the compounds of the present invention can treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis; can ameliorate neural or cardiovascular tissue damage, including that following focal ischemia, myocardial infarction, and reperfusion injury; can treat various diseases and conditions caused or exacerbated by PARP activity; can extend or increase the lifespan or proliferative capacity of cells; can alter the gene expression of senescent cells; can radiosensitize and/or chemosensitize cells.
  • inhibition of PARP activity spares the cells from energy loss, preventing, in the case of neural cells, irreversible depolarization of the neurons, and thus, provides neuroprotection.
  • the present invention further relates to a method of administering a therapeutically effective amount of the above-identified compounds in an amount sufficient to inhibit PARP activity, to treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis, to effect a neuronal activity not mediated by NMDA toxicity, to effect a neuronal activity mediated by NMDA toxicity, to treat neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age- related muscular degeneration, AIDS and other immune senescence diseases, inflammation, gout, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and/or acute pain (such as n
  • the present invention also relates to treating diseases and conditions in an animal which comprises administering to said animal a therapeutically effective amount of the above-identified compounds.
  • the present invention relates to a method of treating, preventing or inhibiting a neurological disorder in an animal, which comprises administering to said animal a therapeutically effective amount of the above-identified compounds.
  • the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic brain injury, physical damage to the spinal cord, stroke associated with brain damage, focal ischemia, global ischemia, reperfusion injury, demyelinating disease and neurological disorder relating to neurodegeneration.
  • the present invention also contemplates the use of compounds of formula (I) for inhibiting PARP activity, for treating, preventing or inhibiting tissue damage resulting from cell damage or death due to necrosis or apoptosis, for treating, preventing or inhibiting a neurological disorder in an animal.
  • preventing neurodegeneration includes the ability to prevent neurodegeneration in patients newly diagnosed as having a neurodegenerative disease, or at risk of developing a new degenerative disease and for preventing further neurodegeneration in patients who are already suffering from or have symptoms of a neurodegenerative disease.
  • treatment covers any treatment of a disease and/or condition in an animal, particularly a human, and includes: (i) preventing a disease and/or condition from occurring in a subject which may be predisposed to the disease and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease and/or condition, i.e., arresting its development; (iii) relieving the disease and/or condition, i.e., causing regression of the disease and/or condition.
  • radiosensitizer is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to ionizing radiation and/or to promote the treatment of diseases which are treatable with ionizing radiation.
  • Diseases which are treatable with ionizing radiation include neoplastic diseases, benign and malignant tumors, and cancerous cells. Ionizing radiation treatment of other diseases not listed herein are also contemplated by the present invention.
  • chemosensitizer is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of cells to chemotherapy and/or promote the treatment of diseases which are treatable with chemotherapeutics.
  • Diseases which are treatable with chemotherapy include neoplastic diseases, benign and malignant tmors and cancerous cells. Chemotherapy treatment of other diseases not listed herein are also contemplated by the present invention.
  • the compounds, compositions and methods of the present invention are particularly useful for treating or preventing tissue damage resulting from cell death or damage due to necrosis or apoptosis.
  • the compounds of the present invention can be "anti-cancer agents", which term also encompasses "anti-tumor cell growth agents” and "anti-neoplastic agents”.
  • the methods of the invention are useful for treating cancers and chemosensitizing and/or radiosensitizing tumor cells in cancers such as ACTH- producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma gallbladder cancer, hairy cell leukemia, head &neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non- Hodgkin's
  • the compounds of the present invention can be used as "radiosensitizer” and/or “chemosensitizer”.
  • Radiosensitizers are known to increase the sensitivity of cancerous cells to the toxic effects of ionizing radiation.
  • hypoxic cell radiosensitizers e.g., 2- nitroimidazole compounds, and benzotriazine dioxide compounds
  • non-hypoxic cell radiosensitizers e.g., halogenated pyrimidines
  • various other potential mechanisms of action have been hypothesized for radiosensitizers in the treatment of disease.
  • radiosensitizers include, but are not limited to, the following: metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5- iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives of the same.
  • Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent.
  • photodynamic radiosensitizers include the following, but are not limited to: hematoporphyrin derivatives, Photofrin, benzoporphyrin derivatives, tin etioporphyrin, pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.
  • Radiosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of radiosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumor with or without additional radiation; or other therapeutically effective compounds for treating cancer or other disease.
  • additional therapeutic agents that may be used in conjunctio ⁇ jwith radiosensitizers include, but are not limited to: 5-fluorouracil, leucovorin, 5' -amino- 5'deoxythymidine, oxygen, carbogen, red cell transfusions, perfluorocarbons (e.g., Fluosol 10 DA), 2,3-DPG, BW12C, calcium channel blockers, pentoxyfylline, antiangiogenesis compounds, hydralazine, and LBSO.
  • 5-fluorouracil leucovorin
  • 5' -amino- 5'deoxythymidine oxygen
  • carbogen red cell transfusions
  • perfluorocarbons e.g., Fluosol 10 DA
  • 2,3-DPG 2,3-DPG
  • BW12C calcium channel blockers
  • pentoxyfylline e.g., 2,3-DPG
  • antiangiogenesis compounds e.g., hydrala
  • chemotherapeutic agents that may be used in conjunction with radiosensitizers include, but are not limited to: adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, docetaxel, doxorubicin, interferon (alpha, beta, gamma), interleukin 2, irinotecan, paclitaxel, topotecan, and therapeutically effective analogs and derivatives of the same.
  • Chemosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to : compounds which promote the incorporation of chemosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumor or other therapeutically effective compounds for treating cancer or other disease.
  • additional therapeutical agents that may be used in conjunction with chemosensitizers include, but are not limited to : methylating agents, toposisomerase I inhibitors and other chemotherapeutic agents such as cisplatin and bleomycin.
  • the compounds of formula (I) can also be used to detect or identify the PARP, and more in particular the PARP-I receptor.
  • the compounds of formula (I) can be labeled.
  • Said label can be selected from the group consisting of a radioisotope, spin label, antigen label, enzyme label fluorescent group or a chemiluminiscent group.
  • an effective amount would be from 0.001 mg/kg to 100 mg/kg body weight, and in particular from 0.005 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 to 500 mg, and in particular 0.1 mg to 200 mg of active ingredient per unit dosage form.
  • DCM dichloromethane
  • DIPE diisopropyl ether
  • DMF diisopropyl ether
  • EtOH is defined as ethanol
  • EtOAc is defined as ethyl acetate
  • MeOH is defined as methanol
  • TEA is defined as triethylamine
  • 'THF is defined as tetrahydrofuran.
  • Tetrakis(isopropanolato)titanium 50ml was added at room temperature to a mixture of 4-oxo-2-(phenylmethyl)- 1-piperidinecarboxylic acid, ethyl ester (0.14 mol) and benzylamine (0.14 mol) in EtOH (300ml) and the mixture was stirred at room temperature for 6 hours.
  • a solution of sodium hydroborate (5.3g) in EtOH (150ml) was added and the mixture was stirred at room temperature for 18 hours.
  • the mixture was hydrolized with water, filtered through celite and evaporated. The residue was taken up in DCM and washed with water. The organic layer was separated, dried (MgSO 4 ), filtered and the solvent was evaporated.
  • Isocyanatotrimethyl- silane (0.00523 mol) was added dropwise at room temperature to a mixture of compound 4 (0.00436 mol) in DCM (20ml). The mixture was stirred at room temperature for 2 hours. The solvent was evaporated till dryness. The residue was taken up in warm MeOH. The precipitate was filtered off and dried in vacuo. The residue (0.8g, 67%) was taken up in MeOH and DCM. The mixture was stirred. The precipitate was filtered off and dried in vacuo, yielding 0.55g (46%) of compound 6, melting point >300°C.
  • Example B 12 Preparation.oXcomgpund.12. A mixture of 1,4-dichlorophthalazine (0.13 mol), l-(phenylmethyl)- 3-pyrrolidinamine (0.12 mol) and sodium carbonate (0.26 mol) in DMF (150ml) was stirred under N 2 at 130 0 C for 4 hours. The mixture was cooled, poured into ice and extracted with DCM. The organic layer was washed with a saturated NaCl solution, dried (MgSO 4 ), filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent : DCMTMeOH 100/0 to 97/3). The pure fractions were collected and evaporated. A part of the residue (38g, 93.5%) was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:2) in 2-propanol, yielding 2.43g of compound 12, melting point 171.8°C.
  • N 2 was bubbled through a mixture of compound 22 (0.00614 mol) in MeOH (30ml) and THF (30ml). Raney nickel (2g) was added portionwise. N 2 was bubbled through the mixture. The mixture was hydrogenated at room temperature under 3 bar pressure for 2 hours. After uptake of H 2 (3 equiv), the catalyst was filtered through celite, washed with DCM and MeOH and the filtrate was evaporated till dryness. The residue was taken up in MeOH and EtOH. The precipitate was filtered off and dried in vacuo. The residue was taken up in warm MeOH. The precipitate was filtered off and drfed in vacuo, yielding 0.47g (24%) of compound 14, melting point >300°C.
  • Table F-I lists the compounds that were prepared according to one of the above Examples.
  • SPA In vitro Scintillation Proximity Assay
  • the assay relies upon the well established SPA technology for the detection of poly(ADP-ribosyl)ation of biotinylated target proteins, i.e histones.
  • This ribosylation is induced using nicked DNA activated PARP-I enzyme and [ 3 H]- nicotinamide adenine dinucleotide ([ 3 H]-NAD + ) as ADP-ribosyl donor.
  • DNAse buffer 10 mM Tris-HCl, pH 7.4; 0.5 mg/ml Bovine Serum Albumine (BSA); 5 mM MgCl 2 -OH 2 O and 1 mM KCl
  • DNAse solution lmg/ml in 0.15 M NaCl
  • the reaction mixture was cooled on ice and dialysed at 4 ° C for respectively 1.5 and 2 hours against 1.5 1 of 0.2 M KCl, and twice against 1.5 1 of 0.01 M KCl for 1.5 and 2 h respectively.
  • the mixture was aliquoted and stored at -20 0 C.
  • Histones (1 mg/ml, type II- A, supplier: Sigma) were biotinylated using the biotinylation kit of Amersham and stored aliquoted at - 20 °C.
  • a stock solution of [ 3 H]-NAD + was made by adding 120 ⁇ l of [ 3 H]- NAD + (0.1 mCi/ml, supplier: NEN) to 6 ml incubation buffer (50 mM Tris/HCl, pH 8; 0.2 mM DTT; 4 mM MgCl 2 ).
  • a solution of 4 mM NAD + (supplier: Roche) was made in incubation buffer (from a 100 mM stock solution in water stored at - 20 0 C).
  • the PARP-I enzyme was produced using art known techniques, i.e. cloning and expression of the protein starting from human liver cDNA.
  • NAD + was added per well into a 96-well microtiterplate.
  • the final concentrations in the incubation mixture were 2 ⁇ g/ml for the biotinylated histones, 2 mg/ml for the PVT- SPA beads, 2 ⁇ g/ml for the nicked DNA and between 5 - 10 ⁇ g/ml for the PARP-I enzyrae.
  • the reaction was terminated by adding 100 ⁇ l of 4 mM NAD + in incubation buffer (final concentration 2 mM) and plates were mixed.
  • the blank value was subtracted from both the control and the sample values.
  • the control sample represented maximal PARP-I enzyme activity.
  • the amount of cpm was expressed as a percentage of the mean cpm value of the controls.
  • ICso-values concentration of the drug, needed to reduce the PARP-I enzyme activity to 50% of the control
  • pICso the negative log value of the ICs 0 - value.
  • 4-amino-l ,8- naphthalimide was included to validate the SPA assay. The tested compounds showed inhibitory activity at the initial test concentration of lO '5 M (see Tabel-2).
  • a mixture of histones (stock solution: 5 mg/ml in H 2 O), NAD + (stock solution: 100 mM in H 2 O), and [ 32 P]-NAD + in incubation buffer (50 mM Tris/HCl, pH 8; 0.2 mM DTT; 4 mM MgCl 2 ) was made.
  • a mixture of the PARP-I enzyme (5 - 10 ⁇ g/ml) and nicked DNA was also made. The nicked DNA was prepared as described in the in vitro SPA for PARP-I inhibitory activity.
  • SPA In vitro Scintillation Proximity Assay
  • Compounds of the present invention were tested in an in vitro assay based on SPA technology with Ni Flash plates (96 or 384 well).
  • the assay relies upon SPA technology for the detection of auto-poly(ADP- ribosyl)ation of TANK-2 protein using [ 3 H]-nicotinamide adenine dinucleotide ([ 3 H]- NAD + ) as ADP-ribosyl donor.
  • a stock solution of [ 3 H]-NAD + /NAD was made by adding 64.6 ⁇ l of [ 3 H]-NAD + (0.1 mCi/ml, supplier: Perkin Elmer) and 46.7 ⁇ l NAD-stock (10.7 mM, stored at - 20 0 C, supplier Roche) to 1888.7 ⁇ l assay buffer (60 mM Tris/HCl, pH 7.4; 0.9 mM DTT; 6 mM MgCl 2 ).
  • the TANK-2 enzyme was produced as described in EP1238063 .
  • the amount of cpm was expressed as a percentage of the mean cpm value of the controls.
  • ICso-values concentration of the drug, needed to reduce the TANK-2 enzyme activity to 50% of the control
  • pICso the negative log value of the ICso-value
  • 3-aminobenzamide and 4-amino-l,8-naphtalimide were included to validate the SPA assay.
  • the assay was described using 96-well plates. In the assay using 384-well plates the same final concentrations were used and volumes were adapted. If 96-well plate results were available these results were incorporated in Table-2, otherwise the results from the 384- well plate assay were shown.
  • the compounds can be further evaluated in a cellular chemo- and/or radiosensitization assay, an assay measuring inhibition of endogenous PARP-1 activity in cancer cell lines and eventually in an in vivo radiosensitization test.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, L1, L2, X, Y, Q and Z have defined meanings.

Description

PHTHALAZINE DERIVATIVES AS PARP INHIBITORS
Field of the invention The present invention relates to inhibitors of PARP and provides compounds and compositions containing the disclosed compounds. Moreover, the present invention provides methods of using the disclosed PARP inhibitors for instance as a medicine.
Background of the invention The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-I) is a member of the PARP enzyme family. This growing family of enzymes consist of PARPs such as, for example: PARP-I1 PARP-2, PARP-3 and Vault-PARP; and Tankyrases (TANKs), such as, for example: TANK-I, TANK-2 and TANK-3. PARP is also referred to as poly(adenosine 5'-diphospho-ribose) polymerase or PARS (poly(ADP-ribose) synthetase).
PARP-I is a major nuclear protein of 116 kDa consisting of three domains : the N- terminal DNA binding domain containing two zinc fingers, the automodification domain and the C-terminal catalytic domain. It is present in almost all eukaryotes. The enzyme synthesizes poly(ADP-ribose), a branched polymer that can consist of over 200 ADP-ribose units. The protein acceptors of poly(ADP-ribose) are directly or indirectly involved in maintaining DNA integrity. They include histones, topoisomerases, DNA and RNA polymerases, DNA ligases, and Ca2+- and Mg2+-dependent endonucleases. PARP protein is expressed at a high level in many tissues, most notably in the immune system, heart, brain and germ-line cells. Under normal physiological conditions, there is minimal PARP activity. However, DNA damage causes an immediate activation of PARP by up to 500-fold.
Tankyrases (TANKs) were identified as components of the human telomeric complex. They have also been proposed to have a role in vesicle trafficking and may serve as scaffolds for proteins involved in various other cellular processes. Telomeres, which are essential for chromosome maintenance and stability, are maintained by telomerase, a specialized reverse transcriptase. TANKs are (ADP-ribose)transferases with some features of both signalling and cytoskeletal proteins. They contain the PARP domain, which catalyses poly-ADP-ribosylation of substrate proteins, the sterile alpha motif, which is shared with certain signalling molecules and the ANK domain, which contains 24 ankyrin repeats homologues to the cytoskeletal protein ankyrin. The ANK domain interacts with a telomeric protein, Telomere Repeat binding Factor-1 (TRF-I). These proteins were therefore named TRFl-interacting, ankyrin-related ADP-ribose polymerase (TANKs) .
One of the more specific functions of TANK is the ADP-ribosylation of TRF-I. Human telomere function requires two telomere-specific DNA binding proteins, TRF-I and TRF-2. TRF-2 protects chromosome ends, and TRF-I regulates telomere length. ADP- ribosylation inhibits the ability of TRF-I to bind to telomeric DNA. This poly-ADP- ribosylation of TRF-I releases TRF-I from the telomeres, opening up the telomeric complex and allow access to telomerase. Therefore, TANK functions as a positive regulator of telomere length., allowing elongation of the telomeres by telomerase.
Among the many functions attributed to PARP, and especially PARP-I, is its major role in facilitating DNA repair by ADP-ribosylation and therefore co-ordinating a number of DNA repair proteins. As a result of PARP activation, NAD+ levels significantly decline. Extensive PARP activation leads to severe depletion of NAD+ in cells suffering from massive DNA damage. The short half -life of poly(ADP-ribose) results in a rapid turnover rate. Once poly(ADP-ribose) is formed, it is quickly degraded by the constitutively active poly(ADP-ribose) glycohydrolase (PARG), together with phosphodiesterase and (ADP-ribose) protein lyase. PARP and PARG form a cycle that converts a large amount of NAD+ to ADP-ribose. In less than an hour, over-stimulation of PARP can cause a drop of NAD+ and ATP to less than 20% of the normal level. Such a scenario is especially detrimental during ischaemia when deprivation of oxygen has already drastically compromised cellular energy output. Subsequent free radical production during reperfusion is assumed to be a major cause of tissue damage. Part of the ATP drop, which is typical in many organs during ischaemia and reperfusion, could be linked to NAD+ depletion due to poly( ADP-ribose) turnover. Thus, PARP or PARG inhibition is expected to preserve the cellular energy level thereby potentiating the survival of ischaemic tissues after insult.
Poly(ADP-ribose) synthesis is also involved in the induced expression of a number of genes essential for inflammatory response. PARP inhibitors suppress production of inducible nitric oxide synthase (iNOS) in macrophages, P-type selectin and intercellular adhesion molecule-1 (ICAM- 1) in endothelial cells. Such activity underlies the strong anti-inflammation effects exhibited by PARP inhibitors. PARP inhibition is able to reduce necrosis by preventing translocation and infiltration of neutrophils to the injured tissues. PARP is activated by damaged DNA fragments and, once activated, catalyzes the attachment of up to 100 ADP-ribose units to a variety of nuclear proteins, including histones and PARP itself. During major cellular stresses the extensive activation of PARP can rapidly lead to cell damage or death through depletion of energy stores. As four molecules of ATP are consumed for every molecule of NAD+ regenerated, NAD+ is depleted by massive PARP activation, in the efforts to re-synthesize NAD+, ATP may also become depleted.
It has been reported that PARP activation plays a key role in both NMDA- and NO- induced neurotoxicity. This has been demonstrated in cortical cultures and in hippocampal slices wherein prevention of toxicity is directly correlated to PARP inhibition potency. The potential role of PARP inhibitors in treating neurodegenerative diseases and head trauma has thus been recognized even if the exact mechanism of action has not yet been elucidated.
Similarly, it has been demonstrated that single injections of PARP inhibitors have reduced the infarct size caused by ischemia and reperfusion of the heart or skeletal muscle in rabbits. In these studies, a single injection of 3-amino-benzamide (10 mg/kg), either one minute before occlusion or one minute before reperfusion, caused similar reductions in infarct size in the heart (32-42%) while 1,5- dihydroxyisoquinoline
(1 mg/kg), another PARP inhibitor, reduced infarct size by a comparable degree (38- 48%) These results make it reasonable to.assume that PARP inhibitors could salvage previously ischaemic heart or reperfusion injury of skeletal muscle tissue.
PARP activation can also be used as a measure of damage following neurotoxic insults resulting from exposure to any of the following inducers like glutamate (via NMDA receptor stimulation), reactive oxygen intermediates, amyloid β-protein, N-methyl-4- ρhenyl-l,2,3,6-tetrahydropyridine (MPTP) or its active metabolite N-methyl-4 phenylpyridine (MPP+), which participate in pathological conditions such as stroke, Alzheimer's disease and Parkinson's disease. Other studies have continued to explore the role of PARP activation in cerebellar granule cells in vitro and in MPTP neurotoxicity. Excessive neural exposure to glutamate, which serves as the predominate central nervous system neurotransmitter and acts upon the N-methyl D-aspartate (NMDA) receptors and other subtype receptors, most often occurs as a result of stroke or other neurodegenerative processes. Oxygen deprived neurons release glutamate in great quantities during ischaemic brain insult such as during a stroke or heart attack. This excess release of glutamate in turn causes over-stimulation (excitotoxicity) of N- methyl-D-aspartate (NMDA), AMPA, Kainate and MGR receptors, which open ion channels and permit uncontrolled ion flow (e.g., Ca2+ and Na+ into the cells and K+ out of the cells) leading to overstimulation of the neurons. The over-stimulated neurons secrete more glutamate, creating a feedback loop or domino effect which ultimately results in cell damage or death via the production of proteases, lipases and free radicals. Excessive activation of glutamate receptors has been implicated in various neurological diseases and conditions including epilepsy, stroke, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, schizophrenia, chronic pain, ischemia and neuronal loss following hypoxia, hypoglycemia, ischemia, trauma, and nervous insult. Glutamate exposure and stimulation has also been implicated as a basis for compulsive disorders, particularly drug dependence. Evidence includes findings in many animal species, as well as in cerebral cortical cultures treated with glutamate or NMDA, that glutamate receptor antagonists (i.e., compounds which block glutamate from binding to or activating its receptor) block neural damage following vascular stroke. Attempts to prevent excitotoxicity by blocking NMDA, AMPA, Kainate and MGR receptors have proven difficult because each receptor has multiple sites to which glutamate may bind and hence finding an effective mix of antagonists or universal antagonist to prevent binding of glutamate to all of the receptor and allow testing of this theory, has been difficult. Moreover, many of the compositions that are effective in blocking the receptors are also toxic to animals. As such, there is presently no known effective treatment for glutamate abnormalities. The stimulation of NMDA receptors by glutamate, for example, activates the enzyme neuronal nitric oxide synthase (nNOS), leading to the formation of nitric oxide (NO), which also mediates neurotoxicity. NMDA neurotoxicity may be prevented by treatment with nitric oxide synthase (NOS) inhibitors or through targeted genetic disruption of nNOS in vitro.
Another use for PARP inhibitors is the treatment of peripheral nerve injuries, and the resultant pathological pain syndrome known as neuropathic pain, such as that induced by chronic constriction injury (CCI) of the common sciatic nerve and in which transsynaptic alteration of spinal cord dorsal horn characterized by hyperchromatosis of cytoplasm and nucleoplasm (so-called "dark" neurons) occurs.
Evidence also exists that PARP inhibitors are useful for treating inflammatory bowel disorders, such as colitis. Specifically, colitis was induced in rats by intraluminal administration of the hapten trinitrobenzene sulfonic acid in 50% ethanol. Treated rats received 3- aminobenzamide, a specific inhibitor of PARP activity. Inhibition of PARP activity reduced the inflammatory response and restored the morphology and the energetic status of the distal colon.
Further evidence suggests that PARP inhibitors are useful for treating arthritis. Further, PARP inhibitors appear to be useful for treating diabetes. PARP inhibitors have been shown to be useful for treating endotoxic shock or septic shock.
PARP inhibitors have also been used to extend the lifespan and proliferative capacity of cells including treatment of diseases such as skin aging, Alzheimer's disease, atherosclerosis, osteoarthritis, osteoporosis, muscular dystrophy, degenerative diseases of skeletal muscle involving replicative senescence, age-related muscular degeneration, immune senescence, AIDS, and other immune senescence disease; and to alter gene expression of senescent cells.
It is also known that PARP inhibitors, such as 3-amino benzamide, affect overall DNA repair in response, for example, to hydrogen peroxide or ionizing radiation.
The pivotal role of PARP in the repair of DNA strand breaks is well established, especially when caused directly by ionizing radiation or, indirectly after enzymatic repair of DNA lesions induced by methylating agents, topoisomerases I inhibitors and other chemotherapeutic agents as cisplatin and bleomycin. A variety of studies using "knockout" mice, trans-dominant inhibition models (over-expression of the DNA- binding domain), antisense and small molecular weight inhibitors have demonstrated the role of PARP in repair and cell survival after induction of DNA damage. The inhibition of PARP enzymatic activity should lead to an enhanced sensitivity of the tumor cells towards DNA damaging treatments.
PARP inhibitors have been reported to be effective in radiosensitizing (hypoxic) tumor cells and effective in preventing tumor cells from recovering from potentially lethal and sublethal damage of DNA after radiation therapy, presumably by their ability to prevent DNA strand break rejoining and by affecting several DNA damage signaling pathways.
PARP inhibitors have been used to treat cancer. In addition, U.S. Patent No.5,177,075 discusses several isoquinolines used for enhancing the lethal effects of ionizing radiation or chemotherapeutic agents on tumor cells. Weltin et al., "Effect of 6(5 - Phenanthridinone), an Inhibitor of Poly(ADP-ribose) Polymerase, on Cultured Tumor Cells", Oncol. Res., 6:9, 399-403 (1994), discusses the inhibition of PARP activity, reduced proliferation of tumor cells, and a marked synergistic effect when tumor cells are co- treated with an alkylating drug.
Rreviews of the state of the art has been published by Li and Zhang in IDrugs 2001, 4(7): 804-812, by Ame et al in Bioassays 2004, 26: 882-883 and by Nguewa et al., in Progress in Biophysic & Molecular Biology 2005, 88: 143-172.
There continues to be a need for effective and potent PARP inhibitors, and more particularly PARP-I inhibitors which produce minimal side effects. The present invention provides compounds, compositions for, and methods of, inhibiting PARP activity for treating cancer and/or preventing cellular, tissue and/or organ damage resulting from cell damage or death due to, for example, necrosis or apoptosis. The compounds and compositions of the present invention are especially useful in enhancing the effectiveness of chemotherapy and radiotherapy where a primary effect of the treatment is that of causing DNA damage in the targeted cells.
Background prior art
The synthesis of aminophthalazinone derivatives is described by Komendy et al, in Acta Chimica Academiae Scientiarum Hungaricae 1981, 106(2): 155-66 and in Acta
Chimica Hungarica 1983, 112(1): 65-82.
EP 156433, published on October 2, 1985 discloses pyridazinamines. The described compounds have anti-viral properties. More in particular compounds No. 77, No.
78, No. 79, No. 80, No. 81, No. 82, No. 83, and No. 84 of the present application are disclosed.
Description of the invention
This invention concerns compounds of formula (I)
(I)
Figure imgf000007_0001
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo- chemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
Q is -C(=O)- or -CR3- wherein R3 is halo or d^alkyl; and when Q is -CR3- the dotted line represents a bond;
each X is independently -N< or -CH<; and when X is -CH< then Y is -N<, or -NH-;
each Y is independently -N<, -NH-, -CH< or -CH2-; except when X is -CH< then Y is -N<, or -NH-;
L1 is a direct bond or a bivalent radical selected from -Ci-6alkanediyl-NH-, -NH- or -NH-Ci-6alkanediyl-NH-;
L2 is a direct bond or a bivalent radical selected from -Ci^alkanediyl-, -C2-6alkenediyl-, carbonyl or -Q-ealkanediyl- substituted with one substituent selected from hydroxy or aryl;
'K1 is hydrogen, nitro, halo or amino;
R2 is hydrogen, Chalky] or arylCi-βalkyl;
the central
Figure imgf000008_0001
be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
Z is hydrogen, hydroxy, Ci^alkyl, C^alkyloxy, aryloxy, amino, cyano, arylCi-galkylamino or benzthiazolylCCi.galkytyamino or a ring system selected from
Figure imgf000009_0001
(a-1) (a-2) (a-3) (a-4)
Figure imgf000009_0002
(a"9> (a-10)
wherein R4 and R5 are each independently selected from hydrogen, halo, C1-6alkyl, Ci-6alkyloxy or trihalomethyl;
aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, Ci^alkyl or Q-βalkyloxy;
with the proviso that when Q is -C(=O)- and X is -N< and Y is -CH< or -CH2- and L1 is a direct bond and L2 is a direct bond, or the bivalent radical -Q^alkanediyl- or -Ci-βalkanediyl- substituted with hydroxy and R1 is hydrogen and R2 is hydrogen or Ci-βalkyl then Z is other than hydrogen, hydroxy or Ci-ealkyl; and when n is i and X is -N< and Y is -N< and L1 and L2 are a direct bond and R1 and R2 are hydrogen and Q is -CR3- wherein R3 is chloro then Z is other than the ring system (a-3).
The compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.
A number of terms used in the foregoing definitions and hereinafter are explained hereunder. These terms are sometimes used as such or in composite terms.
As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; trihalomethyl defines methyl containing three identical or different halo substituents for example trifluoromethyl; C^alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, e.g. methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-methylethyl, 2-methylpropyl, 2-methyl- butyl, 2-methylpentyl and the like; -C^alkanediyl- defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof such as, 2- methylpentanediyl, 3-methylpentanediyl, 2,2-dimethylbutanediyl, 2,3- dimethylbutanediyl and the like; -C2_6alkenediyl- defines bivalent straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as, for example, ethenediyl, 2-propenediyl, 3-butenediyl, 2-pentenediyl, 3- pentenediyl, 3-methyl-2-butenediyl, and the like.
The term "pharmaceutically acceptable salts" means pharmaceutically acceptable acid or base addition salts. The pharmaceutically acceptable acid or base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and non-toxic base addition salt forms which the compounds of formula (T) are able to form. The compounds of formula (I) which have basic propejrties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, ^-aminosalicylic, pamoic and the like acids. The compounds of formula (I) which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a suitable organic or inorganic base. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. The terms acid or base addition salt also comprise the hydrates and the solvent addition foπns which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
The term stereochemically isomeric forms of compounds of formula (I), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
The N-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide, particularly those N-oxides wherein one or more of the piperidine- or piperazine nitrogens are N-oxidized.
Whenever used hereinafter, the term "compounds of formula (I)" is meant to include also the Ν-oxide forms, the pharmaceutically acceptable acid or base addition salts and all stereoisomeric forms.
In Komendy et al, only the synthesis of aminophthalazinone derivatives is described. The compounds described in EP 156433 have anti-viral properties. More in particular compounds No. 77, No. 78, No. 79, No. 80, No. 81, No. 82, No.83, and
No.84 of the present application have been disclosed.
Unexpectedly, it has been found that the compounds of the present invention show
PARP inhibitory activity.
A first group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply: a) n is 0, 1 or 2; b) R2 is hydrogen or arylQ-βalkyl; c) Z is hydrogen, C^alkyl, Q-ealkyloxy, aryloxy, amino, cyano, arylCi-βalkylamino or benzthiazolyl(Ci.6alkyl)amino or a ring system selected from (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10). A second group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply: a) Q is -CR3- wherein R3 is halo or Chalky!; b) each X is -CH<; c) each Y is independently -N< or -NH-; d) L1 is a bivalent radical selected from -Ci-βalkanediyl-NH-, -NH- or
-NH-Ci-galkanediyl-NH-; e) L2 is a bivalent radical selected from -Ca-ealkenediyl-, carbonyl or -Ci-galkanediyl- substituted with aryl; f) R1 is nitro, halo or amino; g) R2 is arylCi-6alkyl; h) Z is Ci-βalkyloxy, aryloxy, amino, cyano, arylQ-βalkylamino or benzthiazolyl(Ci-6alkyl)amino or a ring system selected from (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10).
A third group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply: a) n is 0, 2 or 3; b) Q is -C(=O)- or -CR3- wherein R3 is Ci^alkyl; c) each X is -CH<; d) each Y is independently -CH< or -CH2-; e) L1 is a bivalent radical selected from -Ci-βalkanediyl-NH-, -NH- or
-NH-Ci-ealkanediyl-NH-; f) L2 is a bivalent radical selected from -Ci^alkanediyl-, -C2-6alkenediyl-, carbonyl or -Ci-βalkanediyl- substituted with one substituent selected from hydroxy or aryl; g) R1 is nitro, halo or amino; h) R2 is Ci-6alkyl or arylCi-6alkyl; i) Z is hydrogen, hydroxy, Ci^alkyl, Ci-galkyloxy, aryloxy, amino, cyano, arylCi.6alkylamino or benzthiazoIyl(Ci.6alky])arnino or a ring system selected from
(a-1), (a-2), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10).
A group of preferred compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply: a) n is 1 or 2; b) Q is -C(=O)-; c) Y is -N<, -NH- or -CH<; c) L1 is a direct bond or the bivalent radical -NH-; d) L2 is a direct bond or a bivalent radical selected from carbonyl, -Ci-βalkaπediyl- or
-Ci-galkanediyl- substituted with hydroxy; e) R i l : is hydrogen; f) R2 is hydrogen, arylCi-6alkyl; g) Z is hydrogen, Ci_salkyloxy, aryloxy, amino, or a ring system selected from (a-2) or (a-3); h) R4 and R5 are each independently selected from hydrogen or halo.
A group of most preferred compounds consists of those compounds of formula (I) wherein n is 1 or 2; Q is -C(=O)-; Y is -Nk, -NH- or -CH<; L1 is a direct bond or the bivalent radical -NH-; L2 is a direct bond or a bivalent radical selected from carbonyl, -Ci^alkanediyl- or -Ci.βalkanediyl- substituted with hydroxy; R1 is hydrogen; R2 is hydrogen, arylCi-βalkyl; Z is hydrogen, Ci^alkyloxy, aryloxy, amino, or a ring system selected from (a-2) or (a-3); and R4 and Rs are each independently selected from hydrogen or halo.
The most preferred compounds are compounds No. 41, No. 13, No. 62, No. 26, No.
Figure imgf000013_0001
Figure imgf000014_0001
The compounds of formula (I) can be prepared according to the general methods described in EP156433. The starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art.
Some preparation methods will be described hereinafter in more detail. Other methods for obtaining final compounds of formula (I) are described in the examples.
The compounds of formula (I), wherein L1 is a bond, X is -CH- and Q is -C(=O)-, herein referred to as compounds of formula (I-a), can be prepared by reacting an intermediate of formula (II), with hydrazine. The reaction can be performed in a suitable solvent such as, for example, an alcohol, e.g. methanol, ethanol, propanol and the like. -J. ~ι
Figure imgf000014_0002
The compounds of formula (I), wherein Y is -N< and L is the bivalent radical -Ci-6alkanediyl- substituted with hydroxy, herein referred to as compounds of formula (I-b), can be prepared by reacting an intermediate of formula (V), wherein t is an integer with value 0, 1, 2, 3 or 4, with a compound of formula (I), wherein L2 is a direct bond and Z is hydrogen, herein referred to as compounds of formula (I-c). The reaction can be performed in a reaction-inert solvent such as, for example, N,N-dimethylformamide and the like or an alcohol, e.g. propanol and the like. The addition of an appropriate base such as, for example, an alkali or earth alkaline metal carbonate or hydrogen carbonate, e.g. triethylamine or sodium carbonate, may be utilized.
Figure imgf000015_0001
The compounds of formula (I), wherein Y is -N< and L2 is the optionally substituted bivalent radical -Cj-βalkanediyl-, herein referred to as compounds of formula (I-d), can be prepared by reductively N-alkylating the compounds of formula (I-c), wherein r is an integer with value 0, 1, 2, 3, 4 or 5 with an appropriate carbonyl intermediate of formula (VIII). Said reductive N-alkylation reaction may conveniently be carried out by catalytically hydrogenating a stirred and heated mixture of the reactants in a suitable reaction-inert organic solvent according to art-known catalytic hydrogenating procedures. Suitable solvents are, for example, alcohols, e.g. methanol, ethanol, 2-propanol and the like; cyclic ethers, e.g. 1,4-dioxane and the like; halogenated hydrocarbons, e.g. thrichloromethane and the like; N5N- dimethylformamide; dimethyl sulfoxide and the like; or a mixture of 2 or more of such solvents. The term "art-known catalytic hydrogenating procedures" means that the reaction is carried out under hydrogen atmosphere and in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal, platinum-on-charcoal and the like. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products it may be advantageous to add appropriate catalyst-poison to the reaction mixture, e.g., thiophene and the like.
Figure imgf000015_0002
Art-known catalytic hydrogenating procedures as described above can also be utilized for the preparation of compounds of formula (I-c) (e.g.), or of compounds of formula I, wherein L2 is a direct bond or the bivalent radical -Ci.6alkanediyl- and Z is amino, starting from compounds of formula (I) wherein Z-L2- is arylCi-βalkyl (e.g.) or arylCi.<5alkylamino, herein referred to as compounds of formula (I-e).
Figure imgf000016_0001
Catalytic hydrogenating procedures can also be utilized for the preparation of compounds of formula (I) wherein Z-L2- is aminoCi-βalkyl, herein referred to as compounds of formula (I-i), by converting compounds of formula (I) wherein Z-L2- is cyano-(CH2)r wherein s is an integer with value 1, 2, 3, 4 or 5, herein referred to as compounds of formula (I-j). The reaction is carried out under hydrogen atmosphere and in the presence of Raney Nickel in a mixture of methanol and ammonia.
Figure imgf000016_0002
The compounds of formula (I-c) can also be prepared by deacylating the compounds of formula (I) wherein Z-L2- is -Ci-galkyloxycarbonyl, herein referred to as compounds of formula (I-f), by reacting the starting material with an appropriate acidic or basic solution, such as hydrocloric acid or hydrogen bromide, in a suitable solvent e.g. an alcohol, such as propanol.
Figure imgf000016_0003
The compounds of formula (I), wherein Q is -C(=O)-, herein referred to as compounds of formula (I-g), can be prepared by converting the compounds of formula (I), wherein Q is -CR -, R is halo and the dotted line represents a bond, herein referred to as compounds of formula (I-h), by treatment of a mixture of the compounds of formula (I-h), sodium acetate and acetic acid with an appropriate acidic solution such as hydrochloric acid.
Figure imgf000017_0001
The compounds of formula (I), wherein Y is -N<, herein referred to as compounds of formula (I-k), can be prepared by reacting a compound of formula (I-c), with an intermediate of formula (XI), wherein W is an appropriate leaving group such as, for example, halo, e.g. fluoro, chloro, bromo or iodo, or a sulfonyloxy radical such as methylsulfonyloxy, 4-mefhylphenylsulfonyloxy and the like. The reaction can be performed in a reaction-inert solvent such as, for example, an alcohol, e.g. methanol, ethanol, 2-methoxy-ethanol, propanol, butanol and the like; an ether, e.g. 4, 4-dioxane, l,l'-oxybispropane and the like; a ketone, e.g. 4-methyl-2-pentanone; N,N- dimethylformamide; or nitrobenzene and the like. The addition of an appropriate base such as, foκ example, an alkali or earth alkaline metal carbonate or hydrogen carbonate, e.g. triethylamine or sodium carbonate, may be utilized to pick up the acid which is liberated during the course of the reaction. A small amount of an appropriate metal iodide, e.g., sodium or potassium iodide may be added to promote the reaction. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and the reflux temperature of the reaction mixture and, if desired, the reaction may be carried out at an increased pressure.
Figure imgf000017_0002
In an analogues way, the compounds of formula (I), wherein X is >N- or L1 is -Ci-6alkanediyl-NH-, -NH- (e.g) or -NH-Ci-βalkanediyl-NH-, herein referred to as compounds of formula (1-1), can be prepared by reacting an intermediate of formula (IX), with an intermediate of formula (X) wherein W is as described above.
Figure imgf000018_0001
The compounds of formula (I) may also be converted into each other via art-known reactions or functional group transformations. Some of such transformations are already described hereinabove. Other examples are hydrolysis of carboxylic esters to the corresponding carboxylic acid or alcohol; hydrolysis of amides to the corresponding carboxylic acids or amines; hydrolysis of nitriles to the corresponding amides; amino groups on imidazole or phenyl may be replaced by a hydrogen by art-known diazotation reactions and subsequent replacement of the diazo-group by hydrogen; alcohols may be converted into esters and ethers; primary amines may be converted into secondary or tertiary amines; double bonds may be hydrogenated to the corresponding single bond; an iodo radical on a phenyl group may be converted in to an ester group by carbon monoxide insertion in the presence of a suitable palladium catalyst.
Intermediates of formula (II) can be prepared by reacting an intermediate of formula (III) with a suitable l(3iϊ)-isobenzofuranone of formula (IV) in a mixture of sodium and a suitable solvent such as for example, an alcohol, e.g. ethanol and the like.
Figure imgf000018_0002
The present invention also relates to compounds for use as a medicine wherein said compounds are compounds of formula (I)
Figure imgf000019_0001
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo- chemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
Q is -C(=O)- or -CR3- wherein R3 is halo or Ci-6alkyl; and when Q is -CR3- the dotted line represents a bond;
each X is independently -Ν< or -CH<; and when X is -CHk then Y is -N<, or -NH-;
each Y is independently -N<, -NH-, -CH< or -CH2-; except when X is -CH< then Y is -N<, or -NH-;
Figure imgf000019_0002
-NH- or -NH-CLealkanediyl-NH-;
L2 is a direct bond or a bivalent radical selected from -Ci^alkanediyl-, -C2-6alkenediyl-, carbonyl or -Ci-βalkanediyl- substituted with one substituent selected from hydroxy or aryl;
R1 is hydrogen, nitro, halo or amino;
R2 is hydrogen, Ci^alkyl or arylCi-βalkyl;
the central ' moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
Z is hydrogen, hydroxy,
Figure imgf000019_0003
C].6alkyloxy, aryloxy, amino, cyano, arylCi_6alkylamino or benzthiazolyl(Ci.6alkyl)amino or a ring system selected from
Figure imgf000020_0001
*
(a-1) (a-2) (a-3) (a-4)
Figure imgf000020_0002
(a-9) (a-10)
wherein R4 and R5 are each independently selected from hydrogen, halo, Cuβalkyl, Cμealkyloxy or trihalomethyl;
aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, Q-ealkyl or Q^alkyloxy;
with the proviso that when n is i and X is -N< and Y is -N< and L1 and L2 are a direct bond and R1 and R2 are hydrogen and Q is -CR3- wherein R3 is chloro then Z is other than the ringsystem (a-3).
The compounds of the present invention have PARP inhibiting properties as can be seen from the experimental part hereinunder.
The term "PARP" is used herein to mean a protein having poly-ADP-ribosylation activity. Within the meaning of this term, PARP encompass all proteins encoded by a parp gene, mutants thereof, and alternative slice proteins thereof. Additionally, as used herein, the term "PARP" includes PARP analogues, homologues and analogues of other animals.
The term "PARP", includes but is not limited to PARP-I. Within the meaning of this term PARP-2, PARP-3, Vault-PARP (PARP-4), PARP-7 (TiPARP), PARP-8, PARP-9 (BaI), PARP-10, PARP-Il, PARP-12, PARP-13, PARP-14, PARP-15, PARP-16,
TANK-I, TANK-2, and TANK-3 may be encompassed.
Compounds that inhibit both PARP-I and tankyrase 2 can have advantageous properties in that they have enhanced growth inhibiting activities in cancer cells.
The present invention also contemplates the use of compounds in the preparation of a medicament for the treatment of any of the diseases and disorders in an animal described herein, wherein said compounds are compounds of formula (I)
Figure imgf000021_0001
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo^: chemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
Q is -C(=O)- or -CR3- wherein R3 is halo or Ci.6alkyl; and when Q is -CR3- the dotted line represents a bond;
each X is independently -Ν< or -CH<; and when X is -CH< then Y is -N<, or -NH-;
each Y is independently -N<, -NH-, -CH< or -CH2-; except when X is -CH< then Y is -N<, or -NH-;
L1 is a direct bond or a bivalent radical selected from -Ci_6alkanediyl-NH-, -NH- or -NH-Ci-6alkanediyl-NH-;
L2 is a direct bond or a bivalent radical selected from -CLgalkanediyl-, -Ca-βalkenediyl-, carbonyl or -Ci-ealkanediyl- substituted with one substituent selected from hydroxy or aryl;
R1 is hydrogen, nitro, halo or amino;
R2 is hydrogen, Ci-galkyl or arylCi-βalkyl;
Figure imgf000022_0001
the central ^ " moiety may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
Z is hydrogen, hydroxy, C^alkyl, Ci^alkyloxy, aryloxy, amino, cyano, arylCi.6alkylamino or benzthiazolyl(Ci-6alkyl)amino or a ring system selected from
Figure imgf000022_0002
(a-1) (a-2) (a-3) (a-4)
Figure imgf000022_0003
(a-9) (a- 10)
wherein R >4 . and, D R5 are each independently selected from hydrogen, halo, Ci-βalkyl, Ci^alkyloxy or trihalomethyl; and
aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, Ci^alkyl or Ci^alkyloxy.
In view of their PARP binding properties the compounds of the present invention may be used as reference compounds or tracer compounds in which case one of the atoms of the molecule may be replaced with, for instance, a radioactive isotope.
To prepare the pharmaceutical compositions of this invention, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
The compounds of the present invention can treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis; can ameliorate neural or cardiovascular tissue damage, including that following focal ischemia, myocardial infarction, and reperfusion injury; can treat various diseases and conditions caused or exacerbated by PARP activity; can extend or increase the lifespan or proliferative capacity of cells; can alter the gene expression of senescent cells; can radiosensitize and/or chemosensitize cells. Generally, inhibition of PARP activity spares the cells from energy loss, preventing, in the case of neural cells, irreversible depolarization of the neurons, and thus, provides neuroprotection.
For the foregoing reasons, the present invention further relates to a method of administering a therapeutically effective amount of the above-identified compounds in an amount sufficient to inhibit PARP activity, to treat or prevent tissue damage resulting from cell damage or death due to necrosis or apoptosis, to effect a neuronal activity not mediated by NMDA toxicity, to effect a neuronal activity mediated by NMDA toxicity, to treat neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age- related muscular degeneration, AIDS and other immune senescence diseases, inflammation, gout, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and/or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging, to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; chemosensitize and/or radiosensitize (hypoxic) tumor cells. The present invention also relates to treating diseases and conditions in an animal which comprises administering to said animal a therapeutically effective amount of the above-identified compounds. In particular, the present invention relates to a method of treating, preventing or inhibiting a neurological disorder in an animal, which comprises administering to said animal a therapeutically effective amount of the above-identified compounds. The neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic brain injury, physical damage to the spinal cord, stroke associated with brain damage, focal ischemia, global ischemia, reperfusion injury, demyelinating disease and neurological disorder relating to neurodegeneration.
The present invention also contemplates the use of compounds of formula (I) for inhibiting PARP activity, for treating, preventing or inhibiting tissue damage resulting from cell damage or death due to necrosis or apoptosis, for treating, preventing or inhibiting a neurological disorder in an animal.
The term "preventing neurodegeneration" includes the ability to prevent neurodegeneration in patients newly diagnosed as having a neurodegenerative disease, or at risk of developing a new degenerative disease and for preventing further neurodegeneration in patients who are already suffering from or have symptoms of a neurodegenerative disease.
The term "treatment" as used herein covers any treatment of a disease and/or condition in an animal, particularly a human, and includes: (i) preventing a disease and/or condition from occurring in a subject which may be predisposed to the disease and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease and/or condition, i.e., arresting its development; (iii) relieving the disease and/or condition, i.e., causing regression of the disease and/or condition.
The term "radiosensitizer", as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to ionizing radiation and/or to promote the treatment of diseases which are treatable with ionizing radiation. Diseases which are treatable with ionizing radiation include neoplastic diseases, benign and malignant tumors, and cancerous cells. Ionizing radiation treatment of other diseases not listed herein are also contemplated by the present invention.
The term "chemosensitizer", as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of cells to chemotherapy and/or promote the treatment of diseases which are treatable with chemotherapeutics. Diseases which are treatable with chemotherapy include neoplastic diseases, benign and malignant tmors and cancerous cells. Chemotherapy treatment of other diseases not listed herein are also contemplated by the present invention.
The compounds, compositions and methods of the present invention are particularly useful for treating or preventing tissue damage resulting from cell death or damage due to necrosis or apoptosis. The compounds of the present invention can be "anti-cancer agents", which term also encompasses "anti-tumor cell growth agents" and "anti-neoplastic agents". For example, the methods of the invention are useful for treating cancers and chemosensitizing and/or radiosensitizing tumor cells in cancers such as ACTH- producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma gallbladder cancer, hairy cell leukemia, head &neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non- Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.
Hence the compounds of the present invention can be used as "radiosensitizer" and/or "chemosensitizer".
Radiosensitizers are known to increase the sensitivity of cancerous cells to the toxic effects of ionizing radiation. Several mechanisms for the mode of action of radiosensitizers have been suggested in the literature including: hypoxic cell radiosensitizers ( e.g., 2- nitroimidazole compounds, and benzotriazine dioxide compounds) mimicking oxygen or alternatively behave like bioreductive agents under hypoxia; non-hypoxic cell radiosensitizers (e.g., halogenated pyrimidines) can be analogs of DNA bases and preferentially incorporate into the DNA of cancer cells and thereby promote the radiation-induced breaking of DNA molecules and/or prevent the normal DNA repair mechanisms; and various other potential mechanisms of action have been hypothesized for radiosensitizers in the treatment of disease. Many cancer treatment protocols currently employ radiosensitizers in conjunction with radiation of x-rays. Examples of x-ray activated radiosensitizers include, but are not limited to, the following: metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5- iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives of the same. Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent. Examples of photodynamic radiosensitizers include the following, but are not limited to: hematoporphyrin derivatives, Photofrin, benzoporphyrin derivatives, tin etioporphyrin, pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.
Radiosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of radiosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumor with or without additional radiation; or other therapeutically effective compounds for treating cancer or other disease. Examples of additional therapeutic agents that may be used in conjunctioηjwith radiosensitizers include, but are not limited to: 5-fluorouracil, leucovorin, 5' -amino- 5'deoxythymidine, oxygen, carbogen, red cell transfusions, perfluorocarbons (e.g., Fluosol 10 DA), 2,3-DPG, BW12C, calcium channel blockers, pentoxyfylline, antiangiogenesis compounds, hydralazine, and LBSO. Examples of chemotherapeutic agents that may be used in conjunction with radiosensitizers include, but are not limited to: adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, docetaxel, doxorubicin, interferon (alpha, beta, gamma), interleukin 2, irinotecan, paclitaxel, topotecan, and therapeutically effective analogs and derivatives of the same.
Chemosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to : compounds which promote the incorporation of chemosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumor or other therapeutically effective compounds for treating cancer or other disease. Examples of additional therapeutical agents that may be used in conjunction with chemosensitizers include, but are not limited to : methylating agents, toposisomerase I inhibitors and other chemotherapeutic agents such as cisplatin and bleomycin.
The compounds of formula (I) can also be used to detect or identify the PARP, and more in particular the PARP-I receptor. For that purpose the compounds of formula (I) can be labeled. Said label can be selected from the group consisting of a radioisotope, spin label, antigen label, enzyme label fluorescent group or a chemiluminiscent group.
Those skilled in the art could easily determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective amount would be from 0.001 mg/kg to 100 mg/kg body weight, and in particular from 0.005 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 to 500 mg, and in particular 0.1 mg to 200 mg of active ingredient per unit dosage form.
The following examples illustrate the present invention. Experimental part
Hereinafter, "DCM" is defined as dichloromethane, "DIPE" is defined as diisopropyl ether, "DMF" is defined as N,N-dimethylformamide, "EtOH" is defined as ethanol,
"EtOAc" is defined as ethyl acetate, "MeOH" is defined as methanol and "TEA" is defined as triethylamine, 'THF" is defined as tetrahydrofuran.
A. Preparation of the intermediate compounds
Example Al
Preparation of intermediate 1 f j
l-(Phenylmethyl)- 4-piperidinone (0.2 mol) and l(3/7)-isobenzofuranone (0.2 mol) were added to a dissolved mixture of sodium (0.2 mol) in EtOH absolute (400ml). The mixture was warmed till reflux and refluxed overnight. The mixture was evaporated, water was added and extracted with toluene. The aqueous layer was neutralized with acetic acid and extracted with DCM. The organic layer was dried, filtered off and evaporated, yielding 30.3g (51.7%) of intermediate 1. Example A2 .CLPreparatipjn.Qf intermediate.2
Figure imgf000029_0001
Tetrakis(isopropanolato)titanium (50ml) was added at room temperature to a mixture of 4-oxo-2-(phenylmethyl)- 1-piperidinecarboxylic acid, ethyl ester (0.14 mol) and benzylamine (0.14 mol) in EtOH (300ml) and the mixture was stirred at room temperature for 6 hours. A solution of sodium hydroborate (5.3g) in EtOH (150ml) was added and the mixture was stirred at room temperature for 18 hours. The mixture was hydrolized with water, filtered through celite and evaporated. The residue was taken up in DCM and washed with water. The organic layer was separated, dried (MgSO4), filtered and the solvent was evaporated. The residue (38.5g) was purified by column chromatography over silica gel (20-45μm) (eluent: cyclohexane/EtOAc 60/40). The pure fractions were collected and the solvent was evaporated, yielding 1Og (27%) of intermediate 2. b-LPrep.aration.of intermediate 3.
Figure imgf000029_0002
Intermediate 2 (0.0571 mol) in EtOH (300ml) was hydrogenated at 500C with Pd/C (1Og) as a catalyst for one night under a 3 bar pressure in a Parr apparatus. After uptake of H2 (leq), the catalyst was filtered through celite, washed with EtOH and the filtrate was evaporated, yielding 13.4g (93%) of intermediate 3.
B. Preparation of the final compounds
Example Bl
Figure imgf000029_0003
A mixture of intermediate 1 (0.098 mol) and hydrazine, monohydrate (0.22 mol) in EtOH (350ml) was stirred and refluxed overnight. The mixture was evaporated, water was added and extracted with DCM. The organic layer was dried, filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent: CHCl3/MeOH 98.5/1.5). The pure fractions were collected and evaporated. A part (2.5g) of the residue (10.5g, 33.5%) was crystallized from 2-propanol, yielding 1.5g (20.1%) of compound 1, melting point 222°C. Example B2
3-lPrcparation.of cgmp.ound.23
Figure imgf000030_0001
A mixture of compound 1 (0.028 mol) in MeOH (150ml) was hydrogenated with Pd/C 10% (2g) as a catalyst at 500C. After uptake of H2 (leq), the catalyst was filtered over hyflo and the filtrate was evaporated, compound 23. bI.Prep.aration.of cpmp.ound.2
Figure imgf000030_0002
A mixture of [(4-fluorophenoxy)rnethyl]- oxirane(0.011 mol) and compound 23 (0.01 mol) in 2-propanol (150 ml) was stirred and refluxed overnight. The mixture was cooled with stirring and crystallized. The precipitate was filtered off and dried, yielding 2.4g (60.3%) of compound 2, melting point 226.9°C.
Example B3
£).Prep_aration.of [compound .15
Figure imgf000030_0003
A mixture of compound 11 (0.08 mol) in hydrobromic acid 48 % aqueous (400 ,ml) was stirred and refluxed for 30 min. The solvent was evaporated. The residue was stirred in 2-propanol (300 ml), filtered off and dried. A part (2 g) of the residue (28 g) was recrystallized from MeOH. The precipitate was filtered off and dried, yielding 0.8 g (40%) of compound 15, isolated as a hydrobromic acid salt, melting point >299°C. b)..Prep.aration.of.cpmp.ound,3
Figure imgf000030_0004
.C4H4O4. H2O
A mixture of 4-fluoro-γ-(4-fluorophenyl)- benzenebutanal (0.045 mol), compound 15 (0.045 mol) and potassium acetate (6 g) in MeOH (250 ml) was hydrogenated, overnight at 500C, with Pd/C 10% (3 g) as a catalyst in the presence of thiophene 4% solution (1 ml). After uptake Of H2 (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in DCM. The organic solution was washed with aqueous ammonia, dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: DCM/MeOH 96/4). The desired fractions were collected and the solvent was evaporated. A part(3 g) of the residue (18g, 78%) was dissolved in 2-propanol and converted into the (E)-2-butenedioic acid salt (1:1). The precipitate was filtered off and dried, yielding 2.9 g (60%) of compound 3, melting point 164.4°C.
Example B4
Preparation of.compound .4
Figure imgf000031_0001
.C4H4O4 (2:1) .H2O (2:1)
A mixture of compound 1 (0.028 mol) in MeOH (150ml) was hydrogenated with Pd/C 10% (2g) as a catalyst at 500C. After uptake of H2 (leq), the catalyst was filtered off and the filtrate was evaporated. A part (1.5g) of the residue (6.8g, 100%) was dissolved in 2-propanol and converted into the (E)-2-butenedioic acid salt (2:1) in 2-propanol, yielding 0.7g (37.2%) of compound 4, melting point 264.9°C.
Example B5 PrcEaratip.njof.compgund.5
Figure imgf000031_0002
^Acetic acid, anhydride (0.00523 mol) was added dropwise at room temperature to a mixture of compound 4 (0.00436 mol) and TEA (0.00872 mol) in DCM (10ml). The mixture was stirred at room temperature for 2 hours and poured out into ice water.
DCM was added. The mixture was acidified with HCl IN and extracted with DCM.
The organic layer was separated, basified with potassium carbonate 10%, dried (MgSO4), filtered and the solvent was evaporated. The residue (Ig, 85%) was crystallized from acetonitrile. The precipitate was filtered off and dried in vacuo, yielding 0.88g (75%) of compound 5, melting point 222°C.
Example B6
Figure imgf000031_0003
Isocyanatotrimethyl- silane (0.00523 mol) was added dropwise at room temperature to a mixture of compound 4 (0.00436 mol) in DCM (20ml). The mixture was stirred at room temperature for 2 hours. The solvent was evaporated till dryness. The residue was taken up in warm MeOH. The precipitate was filtered off and dried in vacuo. The residue (0.8g, 67%) was taken up in MeOH and DCM. The mixture was stirred. The precipitate was filtered off and dried in vacuo, yielding 0.55g (46%) of compound 6, melting point >300°C.
Example B7 PreEaration..of.comppuiid 7.
Figure imgf000032_0001
A mixture of compound 4 (0.013 mol), chloro- acetonitrile (0.014 mol) and sodium carbonate (0.065 mol) in DMF (150ml) was stirred at 70°C for 3 hours, cooled, poured out into ice water and extracted with EtOAc. The organic layer was separated, dried (MgSO4), filtered and the solvent was evaporated till dryness. The residue (6.Ig) was purified by column chromatography over silica gel (15-40 μm) (eluent: DCMyMeOHZNH4OH 98/2/0.1). The pure fractions were collected and the solvent was evaporated. The residue was taken up in MeOH. The precipitate was filtered off and dried, yielding 0.33g (10%) of compound 7, melting point 2590C.
Example B8
Figure imgf000032_0002
A mixture of compound 7 (0.0027 mol) in MeOHTNH3 7N (30ml) was hydrogenated under a 3 bar pressure for 24 hours with raney nickel (0.73g) as a catalyst. After uptake of H2 (2 equiv), the catalyst was filtered through celite and the filtrate was evaporated. The residue (0.48g) was purified by column chromatography over silica gel (15-40 μm) (eluent: DCMMeOHTNH4OH 85/14/1 to 83/15/2). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.3g (40.5%) of compound 8, melting point 2020C.
Example B9 a). Preparation of comp.ound.17
Figure imgf000032_0003
A mixture of 1,4-dichlorophthalazine (0.05 mol), 4-piperidinecarbonitrile, monohydrochloride (0.045 mol) and sodium carbonate (0.301 mol) in DMF (100ml) was stirred at 1300C for 5 hours, poured out into ice water and extracted with EtOAc. The organic layer was separated, washed with water, dried (MgSO4), filtered and the solvent was evaporated till dryness. The residue (16g) was purified by column chromatography over silica gel (20-45 μm) (eluent: DCM/MeOH 98/2). The pure fractions were collected and the solvent was evaporated, yielding 7.5g (61.1%) of compound 17. b}.Prep.af.ation.of compound..!.?.
Figure imgf000033_0001
A mixture of compound 17 (0.024 mol) and sodium acetate (0.036 mol) in acetic acid (77ml) was stirred and refluxed for 2 hours. The solvent was evaporated till dryness. The residue was taken up in water. The mixture was basified with potassium carbonate solid. DCM was added. A solid was filtered off and dried, yielding 4.67g (76%) of compound 18, melting point 253°C.
Figure imgf000033_0002
A mixture of compound 18 (0.016 mol) in MeOHTNH37N (150ml) was hydrogenated at room temperature under a 3 bar pressure for 18 hours with raney nickel (4.2g) as a catalyst. After uptake of H2 (2 equiv), the catalyst was filtered through celite and the filtrate was evaporated till dryness. The residue (5.3g) was purified by column chromatography over silica gel (15-40 μm) (eluent: DCMZMeOHTNH4OH 88/12/1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding: 2.8g (67.7%) of compound 9, melting point 182°C.
Example B 10
.a)..Preparatipn of compound .19
Figure imgf000033_0003
A mixture of 1,4-dichlorophthalazine (0.00502 mol), intermediate 3 (0.00452 mol) and sodium carbonate (0.01004 mol) in DMF (15ml) was stirred at 1300C for 5 hours, brought to room temperature, poured out into ice water and extracted with DCM. The organic layer was separated, washed with water, dried (MgSO4), filtered and the solvent was evaporated. The residue (1.2g) was purified by column chromatography over silica gel (15-40 μm )(eluent: DCMZMeOHMH4OH 99/1/0.1 to 85/15/0.1). The pure fractions were collected and the solvent was evaporated. The residue (0.7g, 33%) was crystallized from acetonitrile and diethyl ether. The precipitate was filtered off and dried in vacuo, yielding 0.32g (15%) of compound 19, melting point 161°C. b).Prep.aratiQii.of compound.16
Figure imgf000034_0001
A mixture of compound 19 (0.0087 mol) and sodium acetate (0.01306 mol) in acetic acid (40ml) was stirred and refluxed for 4 hours. The solvent was evaporated till dryness. Hydrochloric acid 10% (40ml) was added. The mixture was stirred and refluxed for 1 hour and then brought to room temperature. DCM was added. The mixture was basified with diluted NH4OH solution and extracted with DCM. The organic layer was separated, washed with water, dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (15-40 μm) (eluent: DCMMeOH 97.5/2.5). The desired fractions were collected and the solvent was evaporated. The residue (1.4g, 40%)was crystallized from diethyl ether. The precipitate was filtered off and dried in vacuo, yielding O.95g (27%) of compound 16, melting point 1400C. s).P.Ϊ"Spara.tion.of cpmpp.und.10
Figure imgf000034_0002
A mixture of compound 16 (0.00492 mol) in HCl 12N (50ml) was stirred and refluxed overnight and then brought to room temperature. The solvent was evaporated till dryness. The residue was taken up in EtOAc. The mixture was basified with potassium carbonate 10% and extracted with EtOAc and a small amount of EtOH. The organic layer was separated, dried (MgS O4), filtered and the solvent was evaporated. The residue was taken up in acetonitrile. The precipitate was filtered off and dried in vacuo, yielding 1.29g (79%) of compound 10, melting point 2380C. Example Bl l a).Preparation.of cpmpound.24
Figure imgf000035_0001
A mixture of 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylic acid, ethyl ester (0.25 mol), 1,4-dichlorophthalazine (0.25 mol) and sodium carbonate (0.25 mol) in DMF (600 ml) was stirred for 4 hours at 1300C. The reaction mixture was cooled and poured out into water. The precipitate was filtered off, washed with water, then dissolved in DCM. The organic solution was dried (MgSO4), filtered and the solvent was evaporated. The residue was crystallized from 2-propanol/DIPE. The precipitate was filtered off and dried, yielding 65 g (72%) of compound 24. fel.Preparation.of comp.ound .1,1
Figure imgf000035_0002
A mixture of compound 24 (0.16 mol) and sodium acetate (0.16 mol) in acetic acid (800 ml) was stirred and refluxed for 5 hours. The solvent was evaporated.
Hydrochloric acid 10% (800 ml) was added to the residue and the reaction mixture was stirred and refluxed for 1 hour, then cooled to room temperature and the resulting precipitate was filtered off, washed with water, then dried. A part (4 g) of the residue (30g) was crystallized from 2-propanol. The precipitate was filtered off and dried, yielding 2.5 g (34%) of compound 11, melting point 218.6°C.
Example B 12 Preparation.oXcomgpund.12.
Figure imgf000035_0003
A mixture of 1,4-dichlorophthalazine (0.13 mol), l-(phenylmethyl)- 3-pyrrolidinamine (0.12 mol) and sodium carbonate (0.26 mol) in DMF (150ml) was stirred under N2 at 1300C for 4 hours. The mixture was cooled, poured into ice and extracted with DCM. The organic layer was washed with a saturated NaCl solution, dried (MgSO4), filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent : DCMTMeOH 100/0 to 97/3). The pure fractions were collected and evaporated. A part of the residue (38g, 93.5%) was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:2) in 2-propanol, yielding 2.43g of compound 12, melting point 171.8°C.
Figure imgf000036_0001
A mixture of l-(3-chloropropoxy)-4-fluoro- benzene (0.025 mol), compound 23 (0.02 mol) and sodium carbonate (0.06 mol) in DMF (150ml) was stirred at 60°C for 12h. The mixture was cooled, poured into ice water, acidified with HCl and neutralized with NH3. The precipitate was filtered off and crystallized from MeOH. The precipitate was filtered off and dried at 6O0C. The residue (2.Ig) was converted into the hydrochloric acid salt (1:1) in 2-propanol. The precipitate was filtered off and washed with 2- propanol and DIPE. The residue was dried at room temperature, yielding 1.2g (14.4%) of compound 13, melting point 227.6°C.
Example B 14 3).Prep.?rati.on.of comp.ound.20
Figure imgf000036_0002
A mixture of l,4-dichloro-6-nitro- phthalazine (0.0557 mol), 4-amino-l- piperidinecarboxylic acid, ethyl ester (0.0501 mol) and sodium carbonate (0.0836 mol) in DMF (150ml) was stirred at 130°C overnight and then brought to room temperature. The solvent was evaporated till dryness. The residue was taken up in DCM. The mixture was poured out into ice water and extracted with DCM. The organic layer was separated, washed with water, dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (20-45 μm) (eluent: DCM/MeOH/NHtOH 98/2/0.4). The pure fractions were collected and the solvent was evaporated. The residue (6.5g) was crystallized from diethyl ether. The precipitate was filtered off and dried in vacuo, yielding 6.2g (29%) of compound 20, melting point 199°C. .tø Preparation of compound 21
Figure imgf000036_0003
A mixture of compound 20 (0.0155 mol) and sodium acetate (0.0233 mol) in acetic acid (50ml) was stirred and refluxed for 3 hours. The solvent was evaporated till dryness. Hydrochloric acid 10% (50ml) was added. The mixture was stirred and refluxed for 1 hour, brought to room temperature, poured out into ice water, basified wi th a concentrated NH4OH solution and stirred. The precipitate was filtered off, washed with water, washed with 2-propanone and diethyl ether and dried in vacuo, yielding 5.3g (95%) of compound 21, melting point 286°C. fi).PrepMatiQn.of cpmppund.22
Figure imgf000037_0001
A mixture of compound 21 (0.11 mol) in hydrochloric acid ION (100ml) was stirred and refluxed overnight and brought to room temperature. The solvent was evaporated till dryness. The residue was taken up in MeOH and EtOH. The mixture was stirred. The precipitate was filtered off and dried in vacuo, yielding 3.5g (98%) of compound 22, melting point 3000C. .Φ.PrepM?LUQΩ.Qf.comp.ound 14
Figure imgf000037_0002
N2 Was bubbled through a mixture of compound 22 (0.00614 mol) in MeOH (30ml) and THF (30ml). Raney nickel (2g) was added portionwise. N2 was bubbled through the mixture. The mixture was hydrogenated at room temperature under 3 bar pressure for 2 hours. After uptake of H2 (3 equiv), the catalyst was filtered through celite, washed with DCM and MeOH and the filtrate was evaporated till dryness. The residue was taken up in MeOH and EtOH. The precipitate was filtered off and dried in vacuo. The residue was taken up in warm MeOH. The precipitate was filtered off and drfed in vacuo, yielding 0.47g (24%) of compound 14, melting point >300°C.
Table F-I lists the compounds that were prepared according to one of the above Examples.
Table F-I
Figure imgf000037_0003
4; Ex. [B4];
mp.
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Pharmacological example
In vitro Scintillation Proximity Assay (SPA) for PARP-I inhibitory activity Compounds of the present invention were tested in an in vitro assay based on SPA technology (proprietary to Amersham Pharmacia Biotech).
In principle, the assay relies upon the well established SPA technology for the detection of poly(ADP-ribosyl)ation of biotinylated target proteins, i.e histones. This ribosylation is induced using nicked DNA activated PARP-I enzyme and [3H]- nicotinamide adenine dinucleotide ([3H]-NAD+) as ADP-ribosyl donor.
As inducer of PARP-I enzyme activity, nicked DNA was prepared. For this, 25 mg of DNA (supplier: Sigma) was dissolved in 25 ml DNAse buffer (10 mM Tris-HCl, pH 7.4; 0.5 mg/ml Bovine Serum Albumine (BSA); 5 mM MgCl2-OH2O and 1 mM KCl) to which 50 μl DNAse solution (lmg/ml in 0.15 M NaCl) was added. After an incubation of 90 min. at 37 0C, the reaction was terminated by adding 1.45 g NaCl, followed by a further incubation at 58 °C for 15 min. The reaction mixture was cooled on ice and dialysed at 4 ° C for respectively 1.5 and 2 hours against 1.5 1 of 0.2 M KCl, and twice against 1.5 1 of 0.01 M KCl for 1.5 and 2 h respectively. The mixture was aliquoted and stored at -20 0C. Histones (1 mg/ml, type II- A, supplier: Sigma) were biotinylated using the biotinylation kit of Amersham and stored aliquoted at - 20 °C. A stock solution of 100 mg/ml SPA polyvinyl toluene) (PVT) beads (supplier: Amersham) was made in PBS. A stock solution of [3H]-NAD+ was made by adding 120 μl of [3H]- NAD+ (0.1 mCi/ml, supplier: NEN) to 6 ml incubation buffer (50 mM Tris/HCl, pH 8; 0.2 mM DTT; 4 mM MgCl2). A solution of 4 mM NAD+ (supplier: Roche) was made in incubation buffer (from a 100 mM stock solution in water stored at - 200C). The PARP-I enzyme was produced using art known techniques, i.e. cloning and expression of the protein starting from human liver cDNA. Information concerning the used protein sequence of the PARP-I enzyme including literature references can be found in the Swiss-Prot database under primary accession number P09874. Biotinylated histones and PVT-SPA beads were mixed and pre-incubated for 30 min. at room temperature. PARP-I enzyme (concentration was lot dependent) was mixed with the nicked DNA and the mixture was pre-incubated for 30 min. at 4 0C. Equal parts of this histones/PVT-SPA beads solution and PARP-I enzyme/DNA solution were mixed and 75 μl of this mixture together with 1 μl of compound in DMSO and 25 μl of [3H]-
NAD+ was added per well into a 96-well microtiterplate. The final concentrations in the incubation mixture were 2 μg/ml for the biotinylated histones, 2 mg/ml for the PVT- SPA beads, 2 μg/ml for the nicked DNA and between 5 - 10 μg/ml for the PARP-I enzyrae. After incubation of the mixture for 15 min. at room temperature, the reaction was terminated by adding 100 μl of 4 mM NAD+ in incubation buffer (final concentration 2 mM) and plates were mixed.
The beads were allowed to sediment for at least 15 min. and plates transferred to a TopCountNXT™ (Packard) for scintillation counting, values were expressed as counts per minute (cpm). For each experiment, controls (containing PARP-I enzyme and DMSO without compound), a blank incubation (containing DMSO but no PARP-I enzyme or compound) and samples (containing PARP-I enzyme and compound dissolved in DMSO) were run in parallel. All compounds tested were dissolved and eventually further diluted in DMSO. In first instance, compounds were tested at a concentration of 10"5 M. When the compounds showed activity at 10 s M, a dose- response curve was made wherein the compounds were tested at concentrations between 10"5M and 10"8M. In each test, the blank value was subtracted from both the control and the sample values. The control sample represented maximal PARP-I enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the controls. When appropriate, ICso-values (concentration of the drug, needed to reduce the PARP-I enzyme activity to 50% of the control) were computed using linear interpolation between the experimental points just above and below the 50 % level. Herein the effects of test compounds are expressed as pICso (the negative log value of the ICs0- value). As a reference compound, 4-amino-l ,8- naphthalimide was included to validate the SPA assay. The tested compounds showed inhibitory activity at the initial test concentration of lO'5 M (see Tabel-2).
In vitro filtration assay for PARP-I inhibitory activity
Compounds of the present invention were tested in an in vitro filtration assay assessing PARP-I activity (triggered in the presence of nicked DNA) by means of its histone poly (ADP-ribosyl)ation activity using [32P]-NAD as ADP-ribosyl donor. The radioactive ribosylated histones were precipitated by trichloroacetic acid (TCA) in 96- well filterplates and the incorporated [ 2P] measured using a scintillation counter
A mixture of histones (stock solution: 5 mg/ml in H2O), NAD+ (stock solution: 100 mM in H2O), and [32P]-NAD+ in incubation buffer (50 mM Tris/HCl, pH 8; 0.2 mM DTT; 4 mM MgCl2) was made. A mixture of the PARP-I enzyme (5 - 10 μg/ml) and nicked DNA was also made. The nicked DNA was prepared as described in the in vitro SPA for PARP-I inhibitory activity. Seventy-five μl of the PARP-I enzyme/DNA mixture together with 1 μl of compound in DMSO and 25 μl of histones-NAD+/[32P]- NAD+ mixture was added per well of a 96-well filterplate (0.45 μm, supplier Millipore). The final concentrations in the incubation mixture were 2 μg/ml for the histones, 0.1 mM for the NAD+, 200 μM (0.5 μC) for the [32P]-NAD+ and 2 μg/ml for the nicked DNA. Plates were incubated for 15 min. at room temperature and the reaction was terminated by the addition of 10 μl ice cold 100% TCA followed by the addition of 10 μl ice-cold BSA solution (1 % in H2O). The protein fraction was allowed to precipitate for 10 min. at 4 0C and plates were vacuum filtered . The plates were subsequently washed with, for each well, 1 ml of 10 % ice cold TCA, 1 ml of 5 % ice cold TCA and 1 ml of 5 % TCA at room temperature. Finally 100 μl of scintillation solution (Microscint 40, Packard) was added to each well and the plates were transferred to a TopCountNXT™ (supplier: Packard) for scintillation counting and values were expressed as counts per minute (cpm). For each experiment, controls (containing PARP-I enzyme and DMSO without compound), a blank incubation (containing DMSO but no PARP-I enzyme or compound) and samples (containing PARP-I enzyme and compound dissolved in DMSO) were run in parallel. AU compounds tested were dissolved and eventually further diluted in DMSO. In first instance, compounds were tested at a concentration of 10"5M. When the compounds showed activity at 10"5M, a dose-response curve was made wherein the compounds were tested at concentrations between 10"5M and 10"8M. In each test, the blank value was subtracted from both the control and the sample values. The control sample represented maximal PARP-I enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the controls. When appropriate, ICso-values (concentration of the drug, needed to reduce the PARP-I enzyme activity to 50% of the control) were computed using linear interpolation between the experimental points just above and below the 50 % level. Herein the effects of test compounds are expressed as pICso (the negative log value of the IC50- value). As a reference compound, 4-amino-l,8-naphthalimide was included to validate the filtration assay. The tested compounds showed inhibitory activity at the initial test concentration of 10"5M (see Tabel-2).
In vitro Scintillation Proximity Assay (SPA) for TANK-2 inhibitory activity Compounds of the present invention were tested in an in vitro assay based on SPA technology with Ni Flash plates (96 or 384 well). In principle, the assay relies upon SPA technology for the detection of auto-poly(ADP- ribosyl)ation of TANK-2 protein using [3H]-nicotinamide adenine dinucleotide ([3H]- NAD+) as ADP-ribosyl donor. A stock solution of [3H]-NAD+/NAD was made by adding 64.6 μl of [3H]-NAD+ (0.1 mCi/ml, supplier: Perkin Elmer) and 46.7 μl NAD-stock (10.7 mM, stored at - 200C, supplier Roche) to 1888.7 μl assay buffer (60 mM Tris/HCl, pH 7.4; 0.9 mM DTT; 6 mM MgCl2). The TANK-2 enzyme was produced as described in EP1238063 . 60 μl of assay buffer, together with 1 μl of compound in DMSO, 20 μl of [3H]-NAD+7NAD and 20 μl of TANK-2 enzyme (final concentration 6 μg/ml) was added per well into a 96-well Ni-coated flash plate (Perkin Elmer). After incubation of the mixture for 120 min. at room temperature, the reaction was terminated by adding 60 μl of stopsolution (42.6 mg NAD in 6 ml H2O). The plates were covered with a plate sealer and placed in a TopCountNXT™ (Packard) for scintillation counting. Values were expressed as counts per minute (cpm). For each experiment, controls (containing TANK-2 enzyme and DMSO without compound), a blank incubation (containing DMSO but no TANK-2 enzyme or compound) and samples (containing TANK-2 enzyme and compound dissolved in DMSO) were run in parallel. All compounds tested were dissolved and eventually further diluted in DMSO. In first instance, compounds were tested at a concentration of 10"sM. When the compounds showed activity at 10"5 M, a dose- response curve was made wherein the compounds were tested at concentrations between 10"5M and 10'8M. In each test, the blank value was subtracted from both the control and the sample values. The control sample represented maximal TANK-2 enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the controls. When appropriate, ICso-values (concentration of the drug, needed to reduce the TANK-2 enzyme activity to 50% of the control) were computed using linear interpolation between the experimental points just above and below the 50 % level. Herein the effects of test compounds are expressed as pICso (the negative log value of the ICso-value). As reference compounds, 3-aminobenzamide and 4-amino-l,8-naphtalimide were included to validate the SPA assay. Herein the assay was described using 96-well plates. In the assay using 384-well plates the same final concentrations were used and volumes were adapted. If 96-well plate results were available these results were incorporated in Table-2, otherwise the results from the 384- well plate assay were shown.
Tabel-2
Figure imgf000048_0001
Figure imgf000049_0001
The compounds can be further evaluated in a cellular chemo- and/or radiosensitization assay, an assay measuring inhibition of endogenous PARP-1 activity in cancer cell lines and eventually in an in vivo radiosensitization test.

Claims

1. A compound of formula (T),
Figure imgf000050_0001
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo- chemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
Q is -C(=O)- or -CR3- wherein R3 is halo or
Figure imgf000050_0002
and when Q is -CR3- the dotted line represents a bond;
each X is independently -Ν< or -CH<; and when X is -CH< then Y is -N<, or -NH-;
each Y is independently -N<, -NH-, -CH< or -CH2-T except when X is -CH< then Y is -N<, or -NH-;
L1 is a direct bond or a bivalent radical selected from -Ci-βalkanediyl-NH-, -NH- or
-NH-Ci-fialkanediyl-NH-;
L2 is a direct bond or a bivalent radical selected from -C^alkanediyl-, -C2-6alkenediyl-, carbonyl or -Ci-βalkanediyl- substituted with one substituent selected from hydroxy or aryl;
R1 is hydrogen, nitro, halo or amino;
R2 is hydrogen, Ci^alkyl or arylCi^alkyl; the central
Figure imgf000051_0001
also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
Z is hydrogen, hydroxy, Ci^alkyl, Ci^alkyloxy, aryloxy, amino, cyano, arylCi.6alkylamino or
Figure imgf000051_0002
or a ring system selected from
Figure imgf000051_0003
(a-1) (a-2) (a-3) (a"4>
Figure imgf000051_0004
wherein R4 and R5 are each independently selected from hydrogen, halo, Q-βalkyl,
Figure imgf000051_0005
or trihalomethyl;
aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, Q^alkyl or Q-βalkyloxy;
with the proviso that when Q is -C(=O)~ and X is -N< and Y is -CEk or -CH2- and L1 is a direct bond and L2 is a direct bond, or the bivalent radical -Ci-galkanediyl- or -Ci-βalkanediyl- substituted with hydroxy and R1 is hydrogen and R2 is hydrogen or Ci.6alkyl then Z is other than hydrogen, hydroxy or Ci-ealkyl; and when n is 1 and X is -N< and Y is -N< and L1 and L2 are a direct bond and R1 and R2 are hydrogen and Q is -CR3- wherein R3 is chloro then Z is other than the ringsystem (a-3).
2. A compound as claimed in claim 1 wherein n is 1 or 2; Q is -C(=O)-; Y is -N<, -NH- or -CH<; L1 is a direct bond or the bivalent radical -NH-; L2 is a direct bond or a bivalent radical selected from carbonyl, -Q-βalkanediyl- or -Ci-δaϊkanediyl- substituted with hydroxy; R1 is hydrogen; R2 is hydrogen, arylQ-βalkyl; Z is hydrogen, Ci^alkyloxy, aryloxy, amino, or a ring system selected from (a-2) or (a-3); and R4 and R5 are each independently selected from hydrogen or halo.
3. A compound according to claim 1 and 2 wherein the compound is compound No. 41, No. 13, No. 62, No. 26, No. 64, No. 2, No. 8, No. 9, No. 34, No.
Figure imgf000052_0001
Figure imgf000053_0001
4. A compound for use as a medicine wherein the compound is a compound of formula (I)
Figure imgf000053_0002
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo- chemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
π is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
Q is -C(=O)- or -CR3- wherein R3 is halo or Q-ealkyl; and when Q is -CR3- the dotted line represents a bond;
each X is independently ~Ν< or -CH<; and when X is -CH< then Y is -N<, or -NH-;
each Y is independently -N<, -NH-, -CH< or -CH2-; except when X is -CH< then Y is -N<, or -NH-;
L1 is a direct bond or a bivalent radical selected from -Ci^alkanediyl-NH-, -NH- or -NH-Ci-ealkanediyl-NH-;
L • 2 i-s a direct bond or a bivalent radical selected from -Ci.6alkanediyl-, -C2^alkenediyl~, carbonyl or -Ci-ealkanediyl- substituted with one substituent selected from hydroxy or aryl; R1 is hydrogen, nitro, halo or amino;
R is hydrogen, Ci-6alkyl or arylCi-6alkyl;
the central
Figure imgf000054_0001
may also be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
Z is hydrogen, hydroxy, Q-βalkyl, Ci-βalkyloxy, aryloxy, amino, cyano, arylCi-ealkylamino or benzthiazolyl(Ci.6alkyl)amino or a ring system selected from
Figure imgf000054_0002
(a-1) (a-2) (a-3) (a-4)
Figure imgf000054_0003
(a-5) (a-6) (a-7) (a-8)
Figure imgf000054_0004
(a-9) (a-10)
wherein R4 and R5 are each independently selected from hydrogen, halo, Ci-βalkyl, Ci^alkyloxy or trihalomethyl;
aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, C^alkyl or Ci^alkyloxy; with the proviso that when n is 1 and X is -N< and Y is -N< and L1 and L2 are a direct bond and R1 and R2 are hydrogen and Q is -CR3- wherein R3 is chloro then Z is other than the ringsystem (a-3).
5. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 4.
6. A process of preparing a pharmaceutical composition as claimed in claim 5 wherein the pharmaceutically acceptable carriers and a compound as claimed in claim 4 are intimately mixed.
7. Use of a compound for the manufacture of a medicament for the treatment of a PARP mediated disorder, wherein said compound is a compound of formula (I)
Figure imgf000055_0001
the N-oxide forms, the pharmaceuticalljfeacceptable addition salts and the stereo- chemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
Q is -C(=O)- or -CR3- wherein R3 is halo or Ci-6alkyl; and when Q is -CR3- the dotted line represents a bond;
each X is independently -Ν< or-CH<; and when X is -CH<then Y is -N<, or -NH-;
each Y is independently -N<, -NH-, -CH< or -CH2-; except when X is -CH< then Y is -N<, or -NH-;
L1 is a direct bond or a bivalent radical selected from -Cj-ealkanediyl-NH-, -NH- or -NH-C1-6alkanediyl-NH-;
L2 is a direct bond or a bivalent radical selected from -Ci^alkanediyl-, -C2-6alkenediyl-, carbonyl or -Ci-ealkanediyl- substituted with one substituent selected from hydroxy or aryl;
R is hydrogen, nitro, halo or amino;
R is hydrogen, C1-6alkyl or arylC^alkyl;
the central
Figure imgf000056_0001
be bridged (i.e. forming a bicyclic moiety) with an ethylene bridge;
Z is hydrogen, hydroxy, Chalky!, C^alkyloxy, aryloxy, amino, cyano, arylCi^alkylamino or benzthiazolyl(Ci.<5alkyl)ammo or a ring system selected from
Figure imgf000056_0002
(a-1) (a-2) (a-3) (a-4)
Figure imgf000056_0003
(a-9) (a-10)
wherein R >4 a _.n_d J x RyS are each independently selected from hydrogen, halo, Ci-βalkyl,
Figure imgf000057_0001
or trihalomethyl; and
aryl is phenyl, or phenyl substituted with one or two substituents each independendly selected from halo, Ci^alkyl or C^alkyloxy.
8. Use according to claim 7 of a PARP inhibitor of formula (I) for the manufacture of a medicament for the treatment of a PARP-I mediated disorder.
9. Use according to claim 7 and 8 wherein the treatment involves chemosensitization.
10. Use according to claims 7 and 8 wherein the treatment involves radiosensitization.
11. A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of formula (I)
Figure imgf000057_0002
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo- chemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;
Q is -C(=O)- or -CR3- wherein R3 is halo or Ci-6alkyl; and when Q is -CR3- the dotted line represents a bond;
each X is independently -Ν< or -CH<; and when X is -CH< then Y is -Nk, or -NH-;
each Y is independently -N<, -NH-, -CH< or -CH2-; except when X is -CH< then Y is -Nk, or -NH-;
L1 is a direct bond or a bivalent radical selected from
Figure imgf000057_0003
-NH- or -NH-Ci.6alkanediyl-NH-;
L2 is a direct bond or a bivalent radical selected from -Ci-salkanediyl-, -Ca-βalkenediyl-, carbonyl or -Ci^alkanediyl- substituted with one substituent selected from hydroxy or aryl;
R1 is hydrogen, nitro, halo or amino;
R2 is hydrogen, Ci-6alkyl or arylCi-βalkyl;
Figure imgf000058_0001
the central ' moiety may also be bridged (i.e. forming a bicyclic with an ethylene bridge;
Z is hydrogen, hydroxy, Ci^alkyl, Q-βalkyloxy, aryloxy, amino, cyano, arylCi.6alkylamino or benzthiazolylCCi-βalkylJamino or a ring system selected from
Figure imgf000058_0002
wherein R ϊ 4 „ a„nd j τ R>5 are each independently selected from hydrogen, halo, C]-6alkyl, Ci-6alkyloxy or trihalomethyl; and
aryl is phenyl, or phenyl substituted with one or two substituents each iπdependendly selected from halo, Ci^alkyl or Ci^alkyloxy.
12. A process for preparing a compound as claimed in claim 1, characterized by a) reacting an intermediate of formula (II) with hydrazine, with the formation of a compound of formula (I-a)
Figure imgf000059_0001
b) reacting an intermediate of formula (V), wherein t is an integer with value 0, 1, 2, 3 or 4, with a compound of formula (I-c)
Figure imgf000059_0002
c) reductively N-alkylating the compound of formula (I-c), wherein r is an integer with value 0, 1, 2, 3, 4 or 5 with an appropriate carbonyl intermediate of formula (VHI)
Figure imgf000059_0003
d) preparing the compounds of formula (I-c) (e.g.), or of compounds of formula I, wherein L2 is a direct bond or the bivalent radical -Ci-όalkanediyl- and Z is amino, starting from compounds of formula (I-e) wherein Z-L2- is arylCi-βalkyl (e.g.) or arylCi-salkylamino
Figure imgf000060_0001
e) converting compounds of formula (I-j) into the compounds of formula (I-i)
Figure imgf000060_0002
f) deacylating the compounds of formula (I-f) with the formation of compounds with formula (I-c)
Figure imgf000060_0003
g) converting the compounds of formula (I-h) into the compounds of formula (I-g)
Figure imgf000060_0004
h) reacting a compound of formula (I-c), with an intermediate of formula (XI), wherein W is an appropriate leaving group, with the formation of compounds of formula (I-k) or
Figure imgf000061_0001
i) reacting an intermediate of formula (IX), with an intermediate of formula (X) with the formation of a compound of formula (1-1).
Figure imgf000061_0002
PCT/EP2005/053030 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors Ceased WO2006003147A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US11/569,889 US7803795B2 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors
CA2569824A CA2569824C (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors
CN2005800222580A CN1980674B (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors
EP05761151.9A EP1771175B1 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors
UAA200612975A UA93351C2 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors
BRPI0512902-8A BRPI0512902A (en) 2004-06-30 2005-06-28 phthalazine derivatives as parp inhibitors
HK07110953.7A HK1105586B (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors
NZ551799A NZ551799A (en) 2004-06-30 2005-06-28 Phthalazine derivatives as PARP inhibitors
ES05761151.9T ES2563954T3 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as PARP inhibitors
EA200700192A EA014955B1 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors
MXPA06014542A MXPA06014542A (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors.
AU2005259189A AU2005259189B2 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as PARP inhibitors
JP2007518607A JP4852540B2 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as PARP inhibitors
IL180410A IL180410A (en) 2004-06-30 2006-12-28 Phthalazine derivatives, compositions and combinations comprising them, process for their preparation and uses thereof for the preparation of medicaments
NO20070557A NO20070557L (en) 2004-06-30 2007-01-30 Phthalazine derivatives as PARP inhibitors
US12/856,218 US8946221B2 (en) 2004-06-30 2010-08-13 Phthalazine derivatives as PARP inhibitors
US14/540,363 US20150072972A1 (en) 2004-06-30 2014-11-13 Phthalazine derivatives as parp inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076886.3 2004-06-30
EP04076886 2004-06-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/569,889 A-371-Of-International US7803795B2 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors
US12/856,218 Division US8946221B2 (en) 2004-06-30 2010-08-13 Phthalazine derivatives as PARP inhibitors

Publications (1)

Publication Number Publication Date
WO2006003147A1 true WO2006003147A1 (en) 2006-01-12

Family

ID=34977026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/053030 Ceased WO2006003147A1 (en) 2004-06-30 2005-06-28 Phthalazine derivatives as parp inhibitors

Country Status (21)

Country Link
US (3) US7803795B2 (en)
EP (1) EP1771175B1 (en)
JP (1) JP4852540B2 (en)
KR (1) KR101211950B1 (en)
CN (1) CN1980674B (en)
AR (1) AR049951A1 (en)
AU (1) AU2005259189B2 (en)
BR (1) BRPI0512902A (en)
CA (1) CA2569824C (en)
EA (1) EA014955B1 (en)
ES (1) ES2563954T3 (en)
IL (1) IL180410A (en)
MX (1) MXPA06014542A (en)
MY (1) MY150781A (en)
NO (1) NO20070557L (en)
NZ (1) NZ551799A (en)
SG (1) SG154433A1 (en)
TW (1) TWI376224B (en)
UA (1) UA93351C2 (en)
WO (1) WO2006003147A1 (en)
ZA (1) ZA200610774B (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042660A3 (en) * 2005-10-12 2007-05-31 Sanofi Aventis Substituted 1-amino-phthalzine derivatives, preparation and therapeutic use thereof
JP2010514785A (en) * 2006-12-28 2010-05-06 アボット・ラボラトリーズ Inhibitors of poly (ADP-ribose) polymerase
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
JP2010539149A (en) * 2007-09-14 2010-12-16 アストラゼネカ アクチボラグ Phthalazinone derivatives
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US7994222B2 (en) 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
US8084623B2 (en) 2006-12-19 2011-12-27 Roche Palo Alto Llc Pyrrolidinyl and piperidinyl ketone derivatives and uses thereof
US8143447B2 (en) 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
US8168644B2 (en) 2008-03-27 2012-05-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8377985B2 (en) 2005-07-18 2013-02-19 Bipar Sciences, Inc. Treatment of cancer
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
US8450486B2 (en) 2003-11-20 2013-05-28 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US8524714B2 (en) 2003-11-20 2013-09-03 Janssen Pharmaceutica, Nv 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US8623872B2 (en) 2004-06-30 2014-01-07 Janssen Pharmaceutica, Nv Quinazolinone derivatives as PARP inhibitors
US8623884B2 (en) 2004-06-30 2014-01-07 Janssen Pharmaceutica, Nv Quinazolinedione derivatives as PARP inhibitors
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
WO2014206524A1 (en) * 2013-06-24 2014-12-31 Merck Patent Gmbh Phthalazine derivatives
CN105272936A (en) * 2014-05-27 2016-01-27 中国科学院上海药物研究所 Nitrogen aryl benzothiazole PARP inhibitors, preparation methods and uses thereof
WO2016036954A1 (en) * 2014-09-05 2016-03-10 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
WO2016123796A1 (en) * 2015-02-06 2016-08-11 Abbvie Inc. Substituted phthalazines
US9579319B2 (en) 2013-05-28 2017-02-28 Redx Pharma Plc Heterocyclic compounds as hedgehog signaling pathway inhibitors
US20170334883A1 (en) 2014-09-05 2017-11-23 Genentech, Inc. Therapeutic compounds and uses thereof
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
US10239861B2 (en) 2015-01-09 2019-03-26 Genetech, Inc. Therapeutic compounds and uses thereof
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
EP3594343A1 (en) 2015-07-23 2020-01-15 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10799501B2 (en) 2015-11-05 2020-10-13 King's College Hospital Nhs Foundation Trust Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L
WO2020232255A1 (en) * 2019-05-14 2020-11-19 The Scripps Research Institute Compounds for the treatment of neurodegenerative and metabolic disorders
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022195102A1 (en) * 2021-03-19 2022-09-22 Centre National De La Recherche Scientifique Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation
WO2024115465A1 (en) * 2022-11-29 2024-06-06 Duke Street Bio Limited Pharmaceutical compounds as parp7 and/or parp1 inhibitors
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803795B2 (en) * 2004-06-30 2010-09-28 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
WO2008024961A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Dihydropyridazine, tetrahydropyridine, chromanone, and dihydronaphthalenone derivatives as heat-shock protein 90 inhibitors
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
US8292573B2 (en) * 2009-04-21 2012-10-23 General Electric Company Flange cooled turbine nozzle
US20110097329A1 (en) * 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
MX2014007093A (en) 2011-12-13 2014-10-13 Buck Inst For Res On Aging METHODS TO IMPROVE MEDICAL THERAPIES.
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US11261466B2 (en) 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
ES3040707T3 (en) 2017-11-01 2025-11-04 Dana Farber Cancer Inst Inc Usp1 or uaf1 inhibitors for use in treating cancer
EP3947351A4 (en) * 2019-03-29 2022-12-07 Board of Regents, The University of Texas System SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF
KR102394110B1 (en) * 2020-01-22 2022-05-04 가톨릭대학교 산학협력단 Novel compound and uses of the same
WO2022081912A2 (en) * 2020-10-15 2022-04-21 Kumquat Biosciences Inc. Heterocycles and uses thereof
WO2022170952A1 (en) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 Polycyclic pyridazinone derivative serving as sos1 inhibitor, preparation method therefor and use thereof
KR102596232B1 (en) * 2021-04-12 2023-11-01 가톨릭대학교 산학협력단 Pharmaceutical composition for preventing or treating transplant rejection reaction containing a novel SD911 compound as an active ingredient
TW202321224A (en) * 2021-07-29 2023-06-01 大陸商上海齊魯製藥研究中心有限公司 Novel PARP7 inhibitor and use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB732581A (en) * 1952-01-18 1955-06-29 Ciba Ltd Manufacture of hydrazine compounds
DE1006423B (en) * 1952-01-18 1957-04-18 Ciba Geigy Process for the preparation of hydrazinophthalazines
US3753988A (en) 1969-05-03 1973-08-21 Aspro Nicholas Ltd Substituted phthalazines
EP0156433A2 (en) 1984-03-26 1985-10-02 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US5231184A (en) * 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
JPH107572A (en) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd Tumor necrosis factor production inhibitor
JP2002284699A (en) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd Remedies for photoreceptor degenerative diseases
WO2003015785A1 (en) 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US3919425A (en) 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
BE792206A (en) 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
US3879393A (en) 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
FR2436781A1 (en) 1978-09-19 1980-04-18 Berri Balzac 3-Amino-(1h,3h)-quinazoline-2,4-di:one derivs. - useful as anxiolytics and sedatives to treat hypertension
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS5976082A (en) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd Novel piperidine derivative
JPS60120872A (en) * 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd Novel heterocyclic compound and cardiotonic agent
PL147465B1 (en) * 1984-03-26 1989-06-30 Janssen Pharmaceutica Nv Method of obtaining novel pyridazionoamine compounds
DK623586A (en) 1985-12-27 1987-06-28 Eisai Co Ltd PIPERIDE INGREDIENTS OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS
MY104343A (en) * 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB8827822D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5374637A (en) 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0391462A1 (en) 1989-04-05 1990-10-10 Janssen Pharmaceutica N.V. Synergistic compositions containing ketanserin
US5160727A (en) 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
IE913473A1 (en) 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
EP0637306B1 (en) 1992-04-23 2001-05-30 Merrell Pharmaceuticals Inc. 4-imidomethyl-1- [2'-phenyl-2'-oxoethyl]- piperidines as serotonin 5ht 2-antagonists, their preparation and use in therapy
TW294595B (en) 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk INHIBITOR OF ADENOSINE INCORPORATION.
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
ATE266673T1 (en) 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma MODIFIED AMINO ACIDS, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
CA2291630A1 (en) 1997-05-30 1998-12-03 Tetsutaro Niizato Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same
JPH10330377A (en) * 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd Piperidine derivative
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2302453A1 (en) 1997-09-16 1999-03-25 Atsuhiro Inaba Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
JP2000191659A (en) * 1999-01-04 2000-07-11 Sumitomo Pharmaceut Co Ltd Tumor necrosis factor production inhibitor
US7265115B2 (en) * 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
IL144340A0 (en) * 1999-01-29 2002-05-23 Abbott Lab Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CN1703403A (en) 2000-10-02 2005-11-30 詹森药业有限公司 Metabotropic glutamate receptor antagonists
IL155645A0 (en) * 2000-10-30 2003-11-23 Kudos Pharm Ltd Phthalazinone derivatives
ITMI20002358A1 (en) 2000-10-31 2002-05-01 Flavio Moroni TIENO DERIVATIVES, 2, 3-C | ISOCHINOLIN-3-ONE AS INHIBITORS OF POLY (DP-RIBOSE) POLYMERASE
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
MXPA04009435A (en) 2002-03-29 2005-01-25 Janssen Pharmaceutica Nv Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands.
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
AR043059A1 (en) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
WO2005054209A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-­ribose) polymerase inhibitors
US7855207B2 (en) 2003-11-20 2010-12-21 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors
ES2360703T3 (en) 2003-12-03 2011-06-08 Ym Biosciences Australia Pty Ltd INHIBITORS OF THE TUBULINA.
ES2551299T3 (en) 2003-12-05 2015-11-17 Janssen Pharmaceutica Nv 2-Quinolinones and 6-substituted 2-quinoxalinones as poly (ADP-ribose) polymerase inhibitors
EP1694653B1 (en) 2003-12-10 2016-01-20 Janssen Pharmaceutica NV 6-(hetero-)cyclohexylalkyl substituted 2-quinolinones/2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
PE20060285A1 (en) 2004-03-30 2006-05-08 Aventis Pharma Inc PYRIDONES SUBSTITUTE AS POL (ADP-RIBOSA) -POLYMERASE (PARP) INHIBITORS
DE102004023332A1 (en) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Quinoxaline-2-one derivatives, crop protection agents containing them, and processes for their preparation and their use
JP4991527B2 (en) 2004-06-01 2012-08-01 ユニバーシティ オブ バージニア パテント ファンデーション Bipartite low molecular weight cancer and angiogenesis inhibitors
US7803795B2 (en) * 2004-06-30 2010-09-28 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
WO2006003146A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
MXPA06014541A (en) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Quinazolinedione derivatives as parp inhibitors.
KR101364762B1 (en) 2005-02-17 2014-02-17 신타 파마슈티칼스 코프. Compounds for the treatment of proliferative disorders
AU2006241825A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
CA2620052A1 (en) 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
WO2007087684A1 (en) 2006-02-03 2007-08-09 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
CN101421268B (en) 2006-02-15 2016-01-06 Abbvie公司 As the pyrazolo quinolone of effective PARP inhibitor
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
HRP20120346T1 (en) 2007-03-08 2012-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as parp and tank inhibitors
AU2008269128B2 (en) * 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB732581A (en) * 1952-01-18 1955-06-29 Ciba Ltd Manufacture of hydrazine compounds
DE1006423B (en) * 1952-01-18 1957-04-18 Ciba Geigy Process for the preparation of hydrazinophthalazines
US3753988A (en) 1969-05-03 1973-08-21 Aspro Nicholas Ltd Substituted phthalazines
EP0156433A2 (en) 1984-03-26 1985-10-02 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US5231184A (en) * 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
JPH107572A (en) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd Tumor necrosis factor production inhibitor
JP2002284699A (en) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd Remedies for photoreceptor degenerative diseases
WO2003015785A1 (en) 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACTA, CHIMICA HUNGARICA, vol. 112, no. 1, 1983, pages 65 - 82
AME ET AL., BIOASSAYS, vol. 26, 2004, pages 882 - 883
BELLASIO E ET AL: "ANTIHYPERTENSIVES. N-1H-PYRROL-1-YL-3-PYRIDAZINAMINES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 27, no. 8, 1984, pages 1077 - 1083, XP001097617, ISSN: 0022-2623 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002, TATSUNO, TORU ET AL: "PARP inhibitors for treatment of retinal degeneration or chemotherapy-induced cell injury", XP002348719, retrieved from STN Database accession no. 2002:747681 *
KOMENDY ET AL., ACTA CHIMICA ACADEMIAE SCIENTIARUM HUNGARICAE, vol. 106, no. 2, 1981, pages 155 - 66
LI, ZHANG, IDRUGS, vol. 4, no. 7, 2001, pages 804 - 812
NGUEWA ET AL., PROGRESS IN BIOPHYSIC & MOLECULAR BIOLOGY, vol. 88, 2005, pages 143 - 172
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 05 30 April 1998 (1998-04-30) *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524714B2 (en) 2003-11-20 2013-09-03 Janssen Pharmaceutica, Nv 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US8450486B2 (en) 2003-11-20 2013-05-28 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US9522905B2 (en) 2004-06-30 2016-12-20 Janssen Pharmaceutica Nv Quinazolinone derivatives as PARP inhibitors
US9255080B2 (en) 2004-06-30 2016-02-09 Janssen Pharmaceutica Nv Quinazolinedione derivatives as PARP inhibitors
US10150757B2 (en) 2004-06-30 2018-12-11 Janssen Pharmaceutica Nv Quinazolinone derivatives as PARP inhibitors
US8623884B2 (en) 2004-06-30 2014-01-07 Janssen Pharmaceutica, Nv Quinazolinedione derivatives as PARP inhibitors
US8623872B2 (en) 2004-06-30 2014-01-07 Janssen Pharmaceutica, Nv Quinazolinone derivatives as PARP inhibitors
US8377985B2 (en) 2005-07-18 2013-02-19 Bipar Sciences, Inc. Treatment of cancer
WO2007042660A3 (en) * 2005-10-12 2007-05-31 Sanofi Aventis Substituted 1-amino-phthalzine derivatives, preparation and therapeutic use thereof
US8143447B2 (en) 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
US7994222B2 (en) 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
US8084623B2 (en) 2006-12-19 2011-12-27 Roche Palo Alto Llc Pyrrolidinyl and piperidinyl ketone derivatives and uses thereof
JP2010514785A (en) * 2006-12-28 2010-05-06 アボット・ラボラトリーズ Inhibitors of poly (ADP-ribose) polymerase
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8778966B2 (en) 2007-03-08 2014-07-15 Janssen Pharmaceutica, Nv Quinolinone derivatives as PARP and tank inhibitors
JP2010539149A (en) * 2007-09-14 2010-12-16 アストラゼネカ アクチボラグ Phthalazinone derivatives
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
US9150540B2 (en) 2008-03-27 2015-10-06 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
US9598396B2 (en) 2008-03-27 2017-03-21 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
US8168644B2 (en) 2008-03-27 2012-05-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US9579319B2 (en) 2013-05-28 2017-02-28 Redx Pharma Plc Heterocyclic compounds as hedgehog signaling pathway inhibitors
WO2014206524A1 (en) * 2013-06-24 2014-12-31 Merck Patent Gmbh Phthalazine derivatives
RU2663623C2 (en) * 2013-06-24 2018-08-07 Мерк Патент Гмбх Phthalazine derivatives
AU2014301669B2 (en) * 2013-06-24 2018-03-01 Merck Patent Gmbh Phthalazine derivatives
US9751842B2 (en) 2013-06-24 2017-09-05 Marck Patent Gmbh Phthalazine derivatives
CN105272936A (en) * 2014-05-27 2016-01-27 中国科学院上海药物研究所 Nitrogen aryl benzothiazole PARP inhibitors, preparation methods and uses thereof
CN105272936B (en) * 2014-05-27 2019-05-17 中国科学院上海药物研究所 A kind of nitrogen aryl benzothiazoles PARP inhibitor and its preparation method and application
CN107074824A (en) * 2014-09-05 2017-08-18 基因泰克公司 Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for the treatment of cancer
US20170334883A1 (en) 2014-09-05 2017-11-23 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016036954A1 (en) * 2014-09-05 2016-03-10 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
CN107074824B (en) * 2014-09-05 2021-01-08 基因泰克公司 Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for the treatment of cancer
US10358437B2 (en) 2014-09-05 2019-07-23 Genentech, Inc. Therapeutic compounds and uses thereof
US10155764B2 (en) 2014-09-05 2018-12-18 Genentech, Inc Therapeutic compounds and uses thereof
US12428373B2 (en) 2014-12-19 2025-09-30 The Broad Institute, Inc. Dopamine D2 receptor ligands
US11498896B2 (en) 2014-12-19 2022-11-15 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10239861B2 (en) 2015-01-09 2019-03-26 Genetech, Inc. Therapeutic compounds and uses thereof
WO2016123796A1 (en) * 2015-02-06 2016-08-11 Abbvie Inc. Substituted phthalazines
EP3594343A1 (en) 2015-07-23 2020-01-15 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US10799501B2 (en) 2015-11-05 2020-10-13 King's College Hospital Nhs Foundation Trust Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
CN114173774A (en) * 2019-05-14 2022-03-11 斯克里普斯研究院 Compounds for the treatment of neurodegenerative and metabolic disorders
WO2020232255A1 (en) * 2019-05-14 2020-11-19 The Scripps Research Institute Compounds for the treatment of neurodegenerative and metabolic disorders
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022195102A1 (en) * 2021-03-19 2022-09-22 Centre National De La Recherche Scientifique Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation
WO2024115465A1 (en) * 2022-11-29 2024-06-06 Duke Street Bio Limited Pharmaceutical compounds as parp7 and/or parp1 inhibitors
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Also Published As

Publication number Publication date
AU2005259189A1 (en) 2006-01-12
TW200610531A (en) 2006-04-01
EP1771175B1 (en) 2015-12-23
US20150072972A1 (en) 2015-03-12
AR049951A1 (en) 2006-09-20
US20110065684A1 (en) 2011-03-17
ZA200610774B (en) 2008-06-25
CN1980674A (en) 2007-06-13
KR20070029246A (en) 2007-03-13
CA2569824C (en) 2013-03-19
EA014955B1 (en) 2011-04-29
JP2008504348A (en) 2008-02-14
AU2005259189B2 (en) 2011-04-21
EA200700192A1 (en) 2007-06-29
US8946221B2 (en) 2015-02-03
CN1980674B (en) 2011-05-25
US7803795B2 (en) 2010-09-28
NZ551799A (en) 2009-11-27
IL180410A (en) 2012-08-30
KR101211950B1 (en) 2012-12-13
JP4852540B2 (en) 2012-01-11
MXPA06014542A (en) 2007-03-23
MY150781A (en) 2014-02-28
UA93351C2 (en) 2011-02-10
US20080139568A1 (en) 2008-06-12
ES2563954T3 (en) 2016-03-16
BRPI0512902A (en) 2008-04-15
SG154433A1 (en) 2009-08-28
TWI376224B (en) 2012-11-11
NO20070557L (en) 2007-01-30
IL180410A0 (en) 2007-06-03
EP1771175A1 (en) 2007-04-11
CA2569824A1 (en) 2006-01-12
HK1105586A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
EP1771175B1 (en) Phthalazine derivatives as parp inhibitors
US8188103B2 (en) Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors
US9255080B2 (en) Quinazolinedione derivatives as PARP inhibitors
IL175756A (en) Use of 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones, inhibitors of (adp-ribose)polymerase, in the manufacture of medicaments for chemosensitization or radiosensitization, some such new compounds and a process for their preparation
HK1105586B (en) Phthalazine derivatives as parp inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11569889

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 551799

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2569824

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/014542

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12006502577

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006/10774

Country of ref document: ZA

Ref document number: 200610774

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005761151

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007518607

Country of ref document: JP

Ref document number: 180410

Country of ref document: IL

Ref document number: 7960/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580022258.0

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077000397

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1200700070

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2005259189

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200700192

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005259189

Country of ref document: AU

Date of ref document: 20050628

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005259189

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020077000397

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005761151

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512902

Country of ref document: BR